HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gambhir, S. S. Articles by Phelps, M. E. Search for Related Content PubMed PubMed Citation Articles by Gambhir, S. S. Articles by Phelps, M. E.

A Tabulated Summary of the FDG PET Literature

The Crump Institute for Molecular Imaging, The Ahmanson Biological Imaging Center, Department of Molecular and Medical Pharmacology, University of California Los Angeles School of Medicine, Los Angeles, California; Duke University School of Medicine, Durham, North Carolina

Key Words: FDG PET • Health Care Financing Administration • oncology • neurology • literature review • cardiology

	INTRODUCTION

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
This special supplement to The Journal of Nuclear Medicine is a detailed tabulation of literature on FDG PET in oncology (1993–June 2000), cardiology (1986–June 2000), and neurology (1980–June 2000). This document is a subset of the original document formally submitted to the Health Care Financing Administration (HCFA) in July 2000 to request expanded Medicare reimbursement for FDG PET. It has been improved by eliminating any errors in tabulation and further clarified as the result of comments from an independent review of the original HCFA submission. This document also differs from the original HCFA submission in that it does not include some background sections and lacks references that were identified but not used because of specific inclusion and exclusion criteria.

The goal of this document is to provide a summary of all FDG PET literature for the specified periods, with tabulated values of sensitivity, specificity, percentage in management changes, etc. This document is not intended to be a formal meta-analysis or cost-effectiveness analysis of the available literature. Instead, it is meant to provide an overview of the available literature, so that future detailed studies can use this document as a starting point.

Because of the difficulty of searching all FDG PET literature, this document inevitably does not include some research articles and abstracts that may be useful. The authors have tried to make the search as comprehensive as possible, but some literature may have been overlooked. Details of the literature search strategy are provided in Appendix A. Although a formal meta-analysis is not performed, a simple weighted averaging of data using various strategies is presented (Appendix B). This weighted averaging is meant to give only a general indication of the overall accuracy values and, therefore, should be interpreted with care. A data pooling analysis is also included.

The document is organized to show, first, how the tabulated data should be interpreted. This is followed by oncologic, cardiac, and neurologic application sections that provide, for each disease process, a disease background section, a case example illustrating the clinical implementation of FDG PET, an explanation of why FDG PET helped, a key management issues section (see also Maisey et al. (285)), and a summary of evidence for FDG PET with management change data for the disease and references to the relevant full literature search (in tabulated form) for the accuracy of FDG PET in specific applications. The numbers of patient studies utilized in calculating summary management changes are displayed in Tables 20 and 24 along with management figures and are embedded (without display) within the individual spreadsheets as selected from the data lines that report management change information. In addition, a summary of results from the literature search on FDG PET in all cancers is provided, as well as a summary of FDG PET literature searched for the oncologic, cardiac, and neurologic applications. A full reference list is also provided at the end. Appendix A gives details on the way in which literature was searched and analyzed, and Appendix B reports some alternate approaches to summarizing the data.

	INTERPRETING SPREADSHEETS IN THIS DOCUMENT

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
This report contains spreadsheets summarizing all FDG PET literature. A spreadsheet is provided for each disease under consideration, along with summary spreadsheets (see Table 1, lung cancer, as an example). On each specific disease spreadsheet, the name of the disease appears in the upper left-hand corner. The data is broken down into applications of FDG PET for diagnosis, staging, diagnosis and staging, recurrence, monitoring response, and other applications. Some diseases include a mixture of these applications and, therefore, have multiple listings in several categories.

A summary for each application is provided in bold. The bolded summary totals for number of patients, number of patient studies, and number of lesions reflect the totals retrieved from the literature for all studies listing data that is inclusive of that application. Each study entry is listed with complete reported data that may include data relevant to several applications. This accounts for data repeated across applications within a given spreadsheet and is discussed in Appendix A. From within each application are selected the respective study data applicable to that application (e.g., recurrence data in instances in which both staging and recurrence data may have been listed in a given entry) and used in the weighted average formulas generating that application’s summary values, which are listed in the statistical ratio columns. These selected N values for total patient studies and total lesions do not appear in the individual spreadsheets but are embedded in the formulas and appear with the application’s summary values in the overall summary sheets at the end of this report. Note that a weighted average is used, which weights studies by the number of patients, so that results obtained with more patients are given more credit. If lesion-by-lesion analysis was performed, a separate value for that analysis is also listed.

All tabular matter is presented here in the form in which it was submitted to HCFA, with the exception of various corrections to tabulation errors found in certain spreadsheets and their carryover to the overall summary sheets, and the placement of table numbers according to the style of this journal.

	ONCOLOGIC APPLICATIONS

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
Lung Cancer

Disease Background.
Lung cancer is among the most frequent and most lethal of cancers striking both men and women. It is the most rapidly increasing tumor in industrialized countries. Most lung cancers are caused by smoking. However, smoking is a less important factor in adenocarcinoma, the lung cancer most rapidly increasing in the United States. Lung cancer accounts for 22% of all cancers in men and 8% of all cancers in women. Five-year survival is achieved by only 13% of all lung cancer patients. Basic treatment for non-small cell lung cancer (NSCLC) is surgical, with only 20% of patients presenting as operable. Patients who are not operable receive palliative chemotherapy or radiation. Small cell lung cancer patients respond well initially to chemotherapy and radiation and generally do not undergo surgery. Their long-term prognosis is poor.

Case Example.
A 62-y-old patient with known NSCLC was evaluated before planned lobectomy. The patient had no symptoms (e.g., headaches). FDG PET revealed extensive metastatic disease to the brain in addition to the primary cancer in the lung.

Why Did FDG PET Help? Because the FDG PET scan showed that the patient had much more extensive disease than previously thought (Fig. 1, arrows), lobectomy was not a management option for this patient. The patient had no symptoms related to the brain metastases, but the FDG PET whole-body survey scan caught tumor spread to the brain.

View larger version (55K): [in this window] [in a new window]   FIGURE 1. Case example, lung cancer.

• Diagnosing the lung mass
  
• Staging NSCLC
  
• Assessing recurrence
  
• Monitoring response to therapy
  

Summary of Evidence for FDG PET in Lung Cancer.
For staging: An estimated 37% change (Table 1) was noted in management effect, based on 1,565 patient studies (Table 24).

Colorectal Cancer

Disease Background.
The colon and the rectum are parts of the large intestine and are responsible for absorption of various substances not absorbed by the small intestine. In western industrialized countries, colorectal cancer is the second most common cause of death from cancer. However, 20-fold variations in international incidence rates have been noted, with the highest rates found in Connecticut in the United States. Primary treatment is surgical, leading to a 50% 5-y survival rate. Adjuvant chemotherapy (chemotherapy before removal of the tumor) is now more commonly used. Radiation is sometimes used for rectal carcinoma and less often for colon cancer. Approximately 20% of patients with recurring cancers are eligible for further resection, with half relapsing early because of previously unidentified metastatic sites. Imaging helps to determine the spread (or lack thereof) of the primary tumor in the colon or rectum.

Case Example.
A patient with carcinoma of the rectum was treated with surgery and radiotherapy. One year later, results of a blood test indicated rising carcinoembryonic antigen (CEA) levels. A CT scan did not reveal the site of tumor recurrence. An FDG PET study showed a liver focus (Fig. 2, arrows), which was proven by biopsy to be recurrent rectal cancer.

View larger version (37K): [in this window] [in a new window]   FIGURE 2. Case example, colorectal cancer.

Key Management Issues.

• Evaluating suspected recurrence and restaging
  
• Assessing response to treatment
  
• Evaluating liver lesions for metastatic disease
  

Summary of Evidence for FDG PET in Colorectal Cancer.
For staging: An estimated 36% change was noted in management effect, based on 236 patient studies (Table 2).

Melanoma

Disease Background.
With an increasing mortality rate second only to that of lung cancer, malignant melanoma is the most rapidly increasing cancer in white populations, with incidence increasing at >5%/y since 1973. The most common cancer striking young women between ages 25 and 29, melanoma accounts for 18% of all cancers in young adults 15–39 y old. Melanoma risk factors include preexisting skin lesions and lighter hair color, with red-haired and blond individuals having 3 and 2 times greater risk than average, respectively. An overall increase in risk appears related to strong solar ultraviolet radiation. Approximately 20% of patients who present with nodal metastases with no distant metastases are cured by surgery. For isolated metastases to the brain and lung, surgery can improve survival. Thus FDG PET’s role in identifying truly isolated metastases is central to the making of rational decisions about radical surgical removal of metastases.

Case Example.
A 63-y-old patient had a melanoma removed from the skin overlying the right scapula (shoulder region). A second metastasis was excised at the nape of the neck. An FDG PET scan was ordered to stage the patient’s cancer. Increased FDG metabolism was seen after surgery at the shoulder site (Fig. 3, far right, top arrow). In addition, multiple metastases were seen within the anterior mediastinum, left lung, left adrenal, left axilla, and para-aortic nodes.

View larger version (47K): [in this window] [in a new window]   FIGURE 3. Case example, melanoma.

Key Management Issues.

• Determining the stage of thick melanoma lesions at presentation
  
• Assessing nodal spread from lesions of intermediate thickness
  
• Confirming the recurrence of disease
  
• Monitoring response to treatment
  
• Restaging before surgical removal of isolated metastases
  

Summary of Evidence for FDG PET in Melanoma.
For staging: An estimated 26% change was noted in management effect, based on 283 patients (Table 3).

Disease Background.
Both Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) are common malignancies that are increasing in frequency. The underlying problem in lymphoma arises from the individual’s white blood cells, cells involved in helping to fight infections. Significant differences exist between HD and NHL, and these differences factor into both diagnosis and treatment. HD begins as a unifocal disease located in a single group of malignant lymph nodes and spreads via adjacent associated lymph node groups. Limited disease is treated appropriately with radiation therapy, resulting in complete cures for a high percentage of patients. Even after recurrence, treatment still may result in permanent cure. Patients with advanced disease have a poorer prognosis and usually require chemotherapy in addition to other treatments. NHL is a multifocal disseminated disease, usually requiring combined chemotherapy, sometimes radiotherapy, and, in some instances, high-dose chemotherapy with bone marrow transplantation. In most patients the disease is ultimately fatal. However, long remission and cure can be induced effectively in high-grade tumors that would be rapidly fatal if untreated. Low-grade NHL, which has a better prognosis untreated, does not respond as well to chemotherapy and consequently can result in a worse prognosis after treatment.

Case Example.
A 27-y-old man with lymphoma underwent an FDG PET study before chemotherapy in July 1999 (Fig. 4, top row). At that time, evidence of cancer was found in the right shoulder and thoracic spine (arrows). The first follow-up FDG PET scan (Fig. 4, middle row) showed nonspecific bone marrow response to chemotherapy (a common finding). The second follow-up scan (Fig. 4, bottom row) demonstrated complete remission, with the right shoulder and thoracic spine regions no longer showing increased FDG metabolism.

View larger version (61K): [in this window] [in a new window]   FIGURE 4. Case example, lymphoma.

Key Management Issues.

• Staging the disease before treatment
  
• Monitoring response to treatment
  
• Detecting recurrence
  
• Making a differential diagnosis
  

Summary of Evidence for FDG PET in Lymphoma.
For staging: An estimated 21% change was noted in management effect, based on 407 patient studies (Table 4).

For recurrence: An estimated 10% change was noted in management effect, based on 158 patient studies (Table 4).

Head and Neck Cancer

Disease Background.
Cancer of the head and neck is relatively uncommon in the western world, occurring in 2%–4% of all cancers. In contrast, it comprises up to 40% of all cancers in some Asian countries. In the western cases, the majority are squamous cell tumors with a variable aggressiveness that depends on site and histological appearance. Strong environmental links have been found with tobacco and alcohol usage and with other factors, such as chemicals, fumes, and viruses. Multidisciplinary teams of head and neck surgical oncologists, radiation oncologists, imaging specialists, and medical oncologists operating in specialized centers are required for good outcomes. Treatment is directed at maintaining the form and function of the head and neck structures as well as eradicating the disease. Because of the need to limit surgery and the fact that local nodal spread is the most important prognostic factor, imaging has an important role in the management of these tumors. After treatment, conventional anatomical imaging procedures prove less useful because of the distortion of anatomy caused by treatment. Therefore, FDG PET is of particular importance in follow-up imaging of suspected recurrence.

Case Example.
A patient with a right alveolar ridge carcinoma was referred for FDG PET scanning before surgery for staging purposes. Results of a CT scan (Fig. 5A, 5C) indicated that the tumor extended superiorly into the maxillary sinus. Registered PET and CT images showed uptake of FDG within the primary site arising from the alveolar ridge (Fig. 5B) but no evidence of tumor within the sinus itself (Fig. 5D). This illustrates how the FDG PET scan can identify the extent of disease when inflammatory tissue and tumor are co-located.

View larger version (119K): [in this window] [in a new window]   FIGURE 5. Case example, head and neck cancer. Reproduced, with permission, from Maisey et al. Atlas of Clinical Positron Emission Tomography. London, UK: Arnold, Hodder Headline Group; 1999.

Key Management Issues.

• Locating the site of primary disease
  
• Determining the extent of primary disease
  
• Staging of lymph node spread
  
• Detecting recurrence
  
• Assessing response to therapy
  

Summary of Evidence for FDG PET in Head and Neck Cancer.
For diagnosis/staging: An estimated 33% change was noted in management effect, based on 15 patient studies (Table 5).

Breast Cancer

Disease Background.
In the United States, breast cancer is currently second only to lung cancer as the leading cancer causing death in women. It is the most common single cause of death for women ages 35–50 y. Cure can be achieved with early diagnosis and treatment, but a multidisciplinary approach is required. Treatment includes surgery, which is becoming progressively less radical, together with chemotherapy. Hormone and radiation therapy also are used ther-apeutically. Imaging is an important part of detection, staging, and management of most breast cancer patients. Although mammography has helped to detect breast cancer in many women, many cancers are missed in women who have dense breasts, implants, or have been treated previously for breast cancer. In addition, more methods are needed to better detect the spread of breast cancer and to monitor treatment and recurrence.

Case Example.
A 61-y-old woman with breast cancer showed several foci of tumor involvement in the chest and spine (Fig. 6, top row) on her initial FDG PET scan. After chemotherapy, an FDG PET study was requested to look for tumor response to chemotherapy (Fig. 6, bottom row). The small foci of FDG accumulation seen throughout the chest and spine clearly had resolved. Post-therapy CT was positive (still showed tumor mass) because of necrosis and edema from therapy.

View larger version (51K): [in this window] [in a new window]   FIGURE 6. Case example, breast cancer.

Key Management Issues.

• Determining if a breast mass is benign or malignant (This is especially difficult in dense breasts, implants, and after treatment. Approximately 60%–85% of breast biopsies are benign.)
  
• Staging of axillary and internal mammary lymph nodes
  
• Detecting metastatic disease
  
• Detecting local or distant recurrence
  
• Assessing the response of the tumor to treatment
  

Summary of Evidence for FDG PET in Breast Cancer.
For diagnosis: An estimated 100% change was noted in management effect, based on six patient studies (Table 6). Because of the limited number of patient studies upon which this management change is based, this value should be interpreted with caution.

For recurrence: An estimated 40% change in management effect, based on 23 patient studies (Table 6).

Brain Tumors

Disease Background.
The incidence of primary brain tumors in the population is 11 in 100,000, with overall metastatic brain disease being more common. Typically, space-occupying lesions are caused by primary tumors, with >50% of patients presenting with some form of epilepsy. New treatments are being introduced, including guided biopsy and surgery (which are frequently image guided), targeted radiation, chemotherapy, and radioactive seed implantation. Outlook remains poor, with survival <1 y for patients with high-grade tumors. Imaging is increasingly required to detect disease, particularly recurrent disease, and in planning and guiding therapy and biopsy. An especially difficult task is determining if cancer has come back after radiation therapy.

Case Example.
The preferred treatment for brain tumors is surgical removal. FDG PET scans are useful for evaluating the efficacy of surgical procedures. A 64-y-old woman with a diagnosis of glioblastoma multiforme (aggressive brain tumor) was operated on to remove the tumor and was treated with radiation. Subsequent contrast-enhanced MRI (Fig. 7, left) suggested possible tumor recurrence. Note the area of contrast accumulation near the surgical region (white arrow). The lack of a corresponding FDG accumulation in that region in the FDG PET image (Fig. 7, right) suggested that the contrast enhancement observed in the MR image was the result of radiation necrosis and that no residual tumor was present at that time.

View larger version (65K): [in this window] [in a new window]   FIGURE 7. Case example, brain tumor.

Key Management Issues.
Initial management.

• Diagnosing and grading the malignancy
  
• Determining the extent for treatment planning
  
• Directing biopsy
  
• Determining prognosis
  

Post-treatment management.

• Differential diagnosis between recurrence and radiation necrosis
  
• Directing biopsy (This helps to determine where in the brain to sample the tissue, by differentiating tumor from necrosis and edema.)
  
• Determining the extent of tumor in treatment planning
  
• Monitoring response to treatment (surgery/radiotherapy/chemotherapy) (This involves differentiating tumor from necrosis and edema to determine how well the treatment affected the tumor.)
  

Summary of Evidence for FDG PET in Brain Tumors.
For recurrence: An estimated 31% change was noted in management effect, based on 89 patient studies (Table 7).

Disease Background.
Ovarian cancer is the fifth leading cause of cancer death in women in the United States, with 14,500 deaths and 25,400 new cases diagnosed each year. Approximately one-third of all new cases will have metastatic disease at the time of diagnosis, with another third developing clinical metastases during the first year after surgical resection. The current recommendation for management of patients without evidence of metastatic disease at 1 y after diagnosis is to perform second-look laparotomy for clinical staging and possible tumor resection. For early-stage ovarian cancer, accurate diagnosis is very difficult.

Cervical cancer is one of the most common cancers, accounting for 6% of all malignancies in women, with an estimated 16,000 new cases of invasive cancer of the cervix and 5,000 deaths in the United States each year. The prognosis for this disease is markedly affected by the extent of disease at the time of diagnosis.

Cancer of the endometrium, a common type of cancer in women, is a disease in which cancer cells are found in the lining of the uterus (endometrium). Cancer of the endometrium is different from cancer of the muscle of the uterus (sarcoma of the uterus). Cancer of the endometrium is the most common pelvic gynecologic malignancy and accounts for 13% of all cancers in women. It is a highly curable tumor.

Case Example.
A 50-y-old woman with a history of ovarian cancer showed rising tumor markers in an annual blood test that looked for possible tumor recurrence. A follow-up CT scan was unable to find the source of the recurrence. An FDG PET study showed that the tumor had metastasized to the right lobe of the liver (Fig. 8, arrows on site of metastasis viewed on 4 different sections through the whole body). No other areas of metastasis were seen.

View larger version (30K): [in this window] [in a new window]   FIGURE 8. Case example, ovarian, cervical, and uterine cancer.

Key Management Issues.

• Staging lymph nodes
  
• Identifying recurrent disease after surgery and radiation
  
• Assessing response to treatment
  

Summary of Evidence for FDG PET in Ovarian, Uterine, and Cervical Cancer.
For recurrence: An estimated 17% change was noted in management effect, based on 30 patient studies (Table 8).

Disease Background.
Bladder cancer is a disease in which cancer cells originate from the bladder wall. Approximately 70%–80% of patients with newly diagnosed bladder cancer will present with superficial bladder tumors. Those tumors that are noninvasive are often curable, and those that are deeply invasive are sometimes cured by surgery, irradiation, or a combination of modalities that includes chemotherapy. Some patients with distant metastases have achieved long-term complete response after treatment with combination chemotherapy regimens. The major prognostic factors in carcinoma of the bladder are the depth of invasion into the bladder wall and the degree of differentiation of the tumor. Transurethral surgery, intravesical medications, and cystectomy (bladder removal) have been used in the management of patients with superficial tumors and are all associated with 5-y survival rates for 55%–80% of patients treated. As with many cancers, the key to management is determining if the bladder cancer has spread beyond the bladder to the local lymph nodes or to distant parts of the body.

Case Example.
A patient with cancer of the bladder was scanned for staging purposes. Focal increased FDG uptake was seen within the posterior aspect (back) of the bladder, indicating primary disease only (Fig. 9, arrow). Mild accumulation of FDG also was seen around a right total hip replacement (Fig. 9A), possibly indicating active inflammation or infection, although the patient did not complain of any hip pain.

View larger version (28K): [in this window] [in a new window]   FIGURE 9. Case example, bladder cancer. Reproduced, with permission, from Maisey et al. Atlas of Clinical Positron Emission Tomography. London, UK: Arnold, Hodder Headline Group; 1999.

Key Management Issues.

• Primary nodal staging
  
• Systemic metastases staging
  

Summary of Evidence for FDG PET in Bladder Cancer.
For staging: An estimated 17% change was noted in management effect, based on 12 patient studies (Table 9).

Gastroesophageal Cancer

Disease Background (Gastric Cancer).
Cancer of the stomach, also called gastric cancer, is a disease in which cancer cells originate from the tissues of the stomach. Cancer of the distal half of the stomach has been decreasing in the United States since the 1930s. However, in the last 2 decades, the incidence of cancer of the cardia and gastroesophageal junction (upper half of the stomach) has been rising rapidly. The incidence of this cancer, especially in patients younger than 40 y, has increased dramatically. In localized distal gastric cancer, >50% of patients can be cured. However, early stage disease accounts for only 10%–20% of all cases diagnosed in the United States. The remaining patients present with metastatic disease in either regional or distant sites. The overall survival rate in these patients at 5 y ranges from almost no survival for patients with disseminated disease to almost 50% survival for patients with localized distal gastric cancers confined to resectable regional disease. Even with apparent localized disease, the 5-y survival rate of patients with proximal gastric cancer is only 10%–15%. Although the treatment of patients with disseminated gastric cancer may result in palliation of symptoms and some prolongation of survival, long remissions are uncommon. Radical surgery represents the standard form of therapy with curative intent. Lesser surgical procedures also may play important roles in palliative therapy for patients with gastric cancer. Neoadjuvant or postoperative chemotherapy and/or radiation therapy are under clinical evaluation.

Disease Background (Esophageal Cancer).
Carcinoma of the esophagus is increasing rapidly in frequency in the west, with the rise most apparent in patients with adenocarcinoma of the esophagus. Much of the increase is thought to be related to reflux esophagitis and Barrett’s esophagus (conditions in which acid from the stomach damages the esophagus), but the exact cause is uncertain. Adenocarcinoma of the esophagus is now more prevalent than squamous cell carcinoma in the United States and western Europe, with most tumors located in the distal esophagus. Esophageal cancer is a treatable disease but is rarely curable. The overall 5-y survival rate in those cases amenable to surgery ranges from 5%–20%. The occasional patient with very early disease has a better chance of survival. Primary treatment modalities include surgery alone or chemotherapy with radiation therapy. Combined modality therapy (chemotherapy plus surgery or chemotherapy and radiation therapy plus surgery) is under clinical evaluation.

Case Example (Gastric Cancer).
A 35-y-old patient underwent surgery for gastric cancer. At the time of surgery, a portion of the stomach was removed around the tumor site. During surgery, it was noted that lymph nodes near the stomach also were involved. The patient therefore underwent chemotherapy to treat for spread of the gastric cancer. A CT scan was performed after 6 mo and showed questionable enlargement of lymph nodes in the abdomen. An FDG PET scan was ordered to determine whether the lymph nodes seen on the CT scan were in fact consistent with tumor involvement. The FDG PET scan (Fig. 10) shows several areas of focal increased FDG accumulation in the midabdomen (arrow), confirming tumor recurrence.

View larger version (54K): [in this window] [in a new window]   FIGURE 10. Case example, gastric cancer.

Case Example (Esophageal Cancer).
A 59-y-old man with known esophageal cancer was referred for FDG PET scanning before surgery. CT demonstrated the presence of the primary tumor but no spread of disease. FDG PET showed uptake in the primary tumor (Fig. 11B, lower arrow) and a lymph node near the trachea (Fig. 11A, arrow, and 11B, upper arrow). The esophageal cancer had spread beyond the esophagus.

View larger version (92K): [in this window] [in a new window]   FIGURE 11. Case example, esophageal cancer. Reproduced, with permission, from Maisey et al. Atlas of Clinical Positron Emission Tomography. London, UK: Arnold, Hodder Headline Group; 1999.

Key Management Issues.

• Staging for possible spread of tumor
  
• Assessing for recurrence
  

Summary of Evidence for FDG PET in Gastroesophageal Cancer.
For diagnosis: An estimated 14% change was noted in management effect, based on 99 patient studies with 276 lesion sites (Table 10).

For diagnosis/staging: An estimated 14% change was noted in management effect, based on 109 patient studies (Table 10).

Hepatocellular Cancer

Disease Background.
Adult primary liver cancer is a disease in which cancer cells start to grow in the tissues of the liver. People who have hepatitis B or C or cirrhosis, a disease of the liver, are more likely than other people to get adult primary liver cancer. Primary liver cancer is different from cancer that has spread from another place in the body to the liver. Hepatocellular carcinoma is a relatively uncommon tumor in the United States, although its incidence is rising. It is the most common cancer in some other parts of the world. Hepatocellular carcinoma is potentially curable by surgical resection, but surgery is the treatment of choice for only the small fraction of patients with localized disease. Prognosis depends on the degree of local tumor replacement and the extent of liver function impairment. Therapy other than surgical resection is best administered as part of a clinical trial. Hepatocellular carcinoma is associated with cirrhosis in 50%–80% of patients. Five percent of patients with cirrhosis eventually develop hepatocellular cancer, which is often multifocal. Childhood liver cancer, also called hepatoma, is a rare disease in which cancer cells are found in the tissues of a child’s liver. Two types of cancer (hepatoblastoma and hepatocellular cancer) start in the liver and are identified by the way the cancer cells look under a microscope. Hepatoblastoma is more common in children younger than 3 y and may have a genetic cause. The overall survival rate for children with hepatoblastoma is 70% but is only 25% for hepatocellular carcinoma.

Case Example.
A patient presented to his doctor with vague abdominal symptoms. The work-up, which eventually included a CT scan, revealed that the patient had enlarged lymph nodes near the portal region of the liver. An FDG PET scan was ordered to further evaluate for tumor. The scan revealed uptake of FDG within a focus in the right lobe of the liver (Fig. 12, center). No other foci were present, indicating that the tumor was confined to the liver. The patient went on to have an appropriate surgery for localized hepatoma.

View larger version (47K): [in this window] [in a new window]   FIGURE 12. Case example, hepatocellular cancer.

Key Management Issues.

• Distinguishing between cirrhosis and hepatoma
  
• Assessing response to treatment and differentiating tumor from necrosis, edema, and scarring
  
• Identifying multifocal lesions
  

Summary of Evidence for FDG PET in Hepatocellular Cancer.
For staging: An estimated 60% change was noted in management effect, based on 20 patient studies (Table 11).

Disease Background.
Adult soft tissue sarcoma is a disease in which cancer cells are found in the soft tissue of part of the body. The soft tissues of the body include the muscles, connective tissues (tendons), vessels that carry blood or lymph, joints, and fat. The prognosis for a patient with adult soft tissue sarcomas depends on several factors, including the patient’s age and the size, histologic grade, and stage of the tumor. Factors associated with a poorer prognosis are age older than 60 y, tumors >5 cm, and high-grade histology. Although low-grade tumors usually are curable by surgery alone, higher-grade sarcomas (as determined by the mitotic index and the presence of hemorrhage and necrosis) are associated with higher local treatment failure rates and increased metastatic potential. Soft tissue sarcomas are rare in children and adolescents. There are many different kinds of soft tissue sarcoma, depending on the soft tissue in which the cancer begins. Rhabdomyosarcoma is the most common type of childhood soft tissue sarcoma. It begins in muscles around the bone and can be found anywhere in the body.

Case Example.
A 41-y-old man had surgery and radiotherapy, first for a liposarcoma in the right thigh and 3 mo later for a solitary metastasis in the abdomen. He developed recurrent disease within the right thigh and was referred for FDG PET scanning. The FDG PET scan showed focal increased metabolism within the right thigh (Fig. 13A, B, and C), indicative of recurrent disease, surrounded by diffuse metabolism secondary to inflammation after surgery. High metabolism of FDG was also noted within lung metastases (Figs. 13C and D).

View larger version (47K): [in this window] [in a new window]   FIGURE 13. Case example, muscle and connective tissue tumors. Reproduced, with permission, from Maisey et al. Atlas of Clinical Positron Emission Tomography. London, UK: Arnold, Hodder Headline Group; 1999.

Key Management Issues.

• Following up sarcoma treatment
  
• Grading sarcoma
  
• Separating benign from malignant masses
  
• Selecting biopsy sites
  
• Assessing extent of sarcomas
  

Summary of Evidence for FDG PET in Muscle and Connective Tissue Tumors.
Management change data for diagnosis and staging and other applications are not directly available from the literature (Table 12).

Disease Background.
Pancreatic carcinoma is common in the United States, with approximately 30,000 patients each year diagnosed with pancreatic adenocarcinomas. Patients with inflammatory processes in the pancreas (pancreatitis) but no cancer can sometimes have high FDG uptake that is indistinguishable from cancers and, thus, must be differentiated from patients with cancer. FDG PET is being applied increasingly in pancreatic cancer diagnosis. Considering the very poor prognosis of pancreatic carcinomas, PET’s greatest role may prove to be in helping to characterize masses appearing in the pancreas, as opposed to more general tumor staging. This is an active area of current investigation.

Case Example.
A 52-y-old woman with a calcified pancreatic mass on CT (Fig. 14A, arrow) was referred for FDG PET scanning because of rising blood tumor markers. No uptake of FDG was seen within the mass (Fig. 14B). The patient was treated conservatively, under the assumption that she had inflammation of the pancreas (pancreatitis). Follow-up over 2 y with CT revealed no changes, indicating that FDG PET was correct and no tumor existed.

View larger version (60K): [in this window] [in a new window]   FIGURE 14. Case example, pancreatic cancer. Reproduced, with permission, from Maisey et al. Atlas of Clinical Positron Emission Tomography. London, UK: Arnold, Hodder Headline Group; 1999.

Key Management Issues.

• Differentiating chronic pancreatic masses from cancer
  
• Staging nodal and liver metastases
  
• Assessing response to chemotherapy
  

Summary of Evidence for FDG PET in Pancreatic Cancer.
For diagnosis: An estimated 50% change was noted in management effect, based on 26 patient studies (Table 13).

For staging: An estimated 36% change was noted in management effect, based on 33 patient studies (Table 13).

For recurrence: An estimated 53% change was noted in management effect, based on 19 patient studies (Table 13).

For monitoring response: An estimated 16% change was noted in management effect, based on 19 patient studies (Table 13).

Prostate Cancer

Disease Background.
Prostate cancer rates increased 141.8% between 1973 and 1994. In 1998, new prostate cancer cases totaled 184,500, or, in other terms, one new case every 3 min. Prostate cancer continues to be the most frequently occurring malignancy (aside from skin cancers), representing 29% of all new cancer cases in American men. One out of every six men is at lifetime risk for prostate cancer. Approximately every 13 min, a life is lost to prostate cancer in the United States. African-Americans have the highest prostate cancer incidence rates in the world, exceeding those for white males in the United States by 34%. Prostate cancer mortality rates are two times higher for African-American men than for white American men.

Case Example.
A 75-y-old man, who was diagnosed with prostate cancer, was followed by blood levels for prostate specific antigen (PSA, a prostate tumor marker). A rising PSA was followed up with a CT scan (Fig. 15, left), which revealed lymph node involvement in the pelvis near the removed prostate. An FDG PET study confirmed what was seen on CT and, in addition, showed spread of cancer into the abdomen and chest (Fig. 15, middle and right).

View larger version (35K): [in this window] [in a new window]   FIGURE 15. Case example, prostate cancer.

Key Management Issues.

• Further evaluation of equivocal bone lesions found with conventional imaging
  
• Differentiating benign from malignant lesions in bone
  
• Assessing treatment response when lesion is imaged initially
  
• Identifying metastatic disease in soft tissue
  

Summary of Evidence for FDG PET in Prostate Cancer.
Management change data for staging patients are not directly available from the literature (Table 14).

Disease Background.
Renal cell cancer, also called renal adenocarcinoma or hypernephroma, can often be cured if diagnosed and treated when still localized to the kidney and to immediately surrounding tissue. The probability of cure is directly related to the stage or degree of tumor dissemination. Even when regional lymphatics or blood vessels are involved with tumor, a significant number of patients can achieve prolonged survival and probable cure. When distant metastases are present, disease-free survival is poor, although occasionally, patients will survive after surgical resection of all known tumor. Because a majority of patients are diagnosed when the tumor is still relatively localized and amenable to surgical removal, approximately 40% of all patients with renal cancer survive 5 y. Occasionally, patients with locally advanced or metastatic disease may exhibit indolent courses lasting several years. Late tumor recurrence many years after initial treatment occurs occasionally. Renal cell cancer is one of the few tumors in which well-documented cases of spontaneous tumor regression in the absence of therapy exist, but this occurs very rarely and may not lead to long-term survival. Surgical resection is the mainstay of treatment of this disease. Even in patients with disseminated tumor, locoregional forms of therapy may play an important role in palliating symptoms of the primary tumor or of ectopic hormone production. Systemic therapy has demonstrated only limited effectiveness.

Case Example.
A 59-y-old man with a history of metastatic renal cell cancer and left kidney removal developed left-sided flank pain. Abdominal-pelvic CT was negative on initial review (Fig. 16, bottom row). FDG PET revealed a focus in the apex of the right lung and in the left flank (Fig. 16, top row, arrows). Because of the abnormality in the region of the left flank, the CT was reviewed again and a mass located in the posterior abdominal wall was found. Biopsy revealed metastasis from renal cell cancer.

View larger version (71K): [in this window] [in a new window]   FIGURE 16. Case example, renal cell cancer.

Key Management Issues.

• Detecting metastatic disease
  
• Assessing response of metastases to chemotherapy
  
• Determining nature of renal masses
  

Summary of Evidence for FDG PET in Renal Cell Cancer.
Management change data for diagnosis and staging and other applications are not directly available from the literature (Table 15).

Disease Background.
Cancer of the testicle, a rare type of cancer, is a disease in which cancer cells are found in the tissues of one or both of a man’s testicles. Cancer of the testicle is the most common cancer in men 15–35 y old. Men who have an undescended testicle (a testicle that has never moved down into the scrotum) are at higher risk of developing cancer of the testicle. This is true even if surgery has been performed to place the testicle in the appropriate place in the scrotum. Prognosis and choice of treatment depend on the stage of the cancer and the patient’s general state of health.

Case Example.
A 27-y-old man with testicular cancer had his left testicle removed. An abdominal CT scan indicated an enlarged lymph node in the lower abdomen. A CT-guided biopsy was performed but did not reveal cancer. An FDG PET scan was ordered to make sure the biopsy was not wrong. The scan showed a focus of activity in the abdominal lymph node (Fig. 17, arrows), suggesting cancer spread. A repeat biopsy confirmed tumor in the abdominal lymph node site.

View larger version (77K): [in this window] [in a new window]   FIGURE 17. Case example, testicular cancer.

Key Management Issues.

• Monitoring response to treatment
  
• Staging of primary disease
  
• Assessing residual mass
  
• Further evaluating raised markers
  

Summary of Evidence for FDG PET in Testicular Cancer.
For staging: An estimated 22% change was noted in management effect, based on 27 patient studies (Table 16).

Thyroid Cancer

Disease Background.
Cancer of the thyroid is a disease in which cancer cells are found in the tissues of the thyroid gland. People who have been exposed to large amounts of radiation or who have had radiation treatment for medical problems in the head and neck have a higher chance of getting thyroid cancer. The cancer may not occur until 20 y or longer after radiation treatment. The four main types of cancer of the thyroid are: papillary, follicular, medullary, and anaplastic. The chance of recovery depends on the type of thyroid cancer, whether it is only in the thyroid or has spread to other parts of the body (stage), and the patient’s age and overall health. Some types of thyroid cancer grow much faster than others. Although thyroid cancer is relatively uncommon, it is nonetheless the most common malignancy of the endocrine system. Differentiated tumors (papillary or follicular) are highly treatable and usually curable. Poorly differentiated cancers (medullary or anaplastic) are much less common but aggressive, metastasize early, and have a much poorer prognosis. The incidence of this malignancy has been increasing over the last decade. The prognosis for differentiated carcinoma is better for patients younger than 40 y and who have no extracapsular extension or vascular invasion. Age appears to be the single most important prognostic factor. Thyroid cancer commonly presents as a cold nodule within the thyroid gland. The overall incidence of cancer in a cold nodule is 12%–15% but is higher in patients younger than 40 y.

Case Example.
A 62-y-old patient underwent surgery of the left thyroid for thyroid cancer. Routine yearly monitoring revealed elevated blood levels of calcitonin. A CT scan was ordered and was normal. An FDG PET scan revealed increased FDG accumulation in the neck (Fig. 18, arrows), which was confirmed by biopsy to be residual thyroid cancer.

View larger version (74K): [in this window] [in a new window]   FIGURE 18. Case example, thyroid cancer. Reproduced, with permission, from Maisey et al. Atlas of Clinical Positron Emission Tomography. London, UK: Arnold, Hodder Headline Group; 1999.

Key Management Issues.

• Further evaluation when whole-body ¹³¹I scan is negative but thyroglobulin (Tg) levels are rising in a patient with known differentiated thyroid cancer
  
• Further evaluation for medullary thyroid cancer when rising calcitonin level and initial imaging with dimercaptosuccinic acid V, octreoscan, or metaiodobenzylguanidine is negative.
  

Summary of Evidence for FDG PET in Thyroid Cancer.
For staging: An estimated 22% change was noted in management effect, based on 60 patient studies (Table 17).

For recurrence: An estimated 53% change was noted in management effect, based on 21 patient studies (Table 17).

Unknown Primary Tumor

Disease Background.
Detection of the unknown primary lesion is very difficult. In many cases, patients present with obvious metastatic disease, often adenocarcinoma, in which the location of the primary lesion may never be found. In some cases, knowledge of the primary site is important, because the type of treatment may vary (e.g., breast cancers are more responsive to some treatments than are renal cancers). This knowledge also can be helpful in resection or treatment for cure of the primary lesion and metastases (e.g., head and neck cancers). FDG PET is useful in locating primary tumors after metastatic disease has appeared in regional lymph nodes. FDG PET is being applied increasingly in the search for unknown primary lesions. This application is still in evolution, but FDG PET should be considered strongly in the work-up of the unknown primary.

Case Example.
A 49-y-old woman presented with lymph node enlargement in the neck. Physical examination, CT, and mammography performed twice all failed to reveal the source of the primary cancer. An FDG PET study showed that the primary cancer was in the left breast (nonpalpable). The lymph node involvement was not seen in the sections shown in Figure 19.

View larger version (83K): [in this window] [in a new window]   FIGURE 19. Case example, unknown primary tumor.

Key Management Issues.

• Identifying primary site to determine treatment and evaluate for possible resection
  

Summary of Evidence for FDG PET in Unknown Primary Cancer.
For staging: An estimated 29% change was noted in management effect, based on 285 patient studies (Table 18). (See Table 19 for the results of the literature search on FDG PET in miscellaneous tumors.)

	CARDIAC APPLICATIONS

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
Myocardial Viability

Disease Background.
A key issue for imaging is to determine whether a given portion of the heart is viable. This means looking at areas of the heart that are not functioning properly and determining whether tissue is still alive and can recover if the blood supply is restored by revascularization. This is a biochemical question. Biochemists and biologists have shown that glucose is a protective substrate to the heart when blood flow is limited. FDG PET helps to determine viability, because those areas of the myocardium that are viable will have glucose metabolism. On the other hand if the myocardial muscle is dead, it will not have any glucose metabolism. The patient whose myocardial muscle demonstrates no glucose metabolism will not benefit from having blood supply re-established to the muscle. Such a patient would need medical therapy or a heart transplant. About 35% of coronary artery disease patients who receive bypass surgery or angioplasty to revascularize the heart do not show improvement in cardiac function because the affected tissue is not reversible (i.e., is dead).

Case Example.
A 57-y-old patient with a previous heart attack was evaluated by echocardiography (echo), which showed that the patient’s left ventricular ejection fraction (percentage of blood ejected from the heart during cardiac cycle) was compromised at 35% (normal >55%) and that wall motion was abnormal. An FDG PET cardiac study was requested to evaluate for viable, reversible myocardium. The PET image on the left in Figure 20 was obtained by using ¹³N ammonia in a study of blood perfusion to the heart. ¹³N ammonia has been approved by the U.S. Food and Drug Administration for imaging blood flow in the heart. The donut-like structure is the heart muscle, and the chamber it encloses is the left ventricle. The defect (arrow) seen toward the right side of the donut is an area of compromised blood flow. The image on the right in Figure 20 is the FDG PET glucose metabolism study, and it clearly shows FDG metabolism in the same area that is compromised with regard to blood flow. This patient, therefore, would be likely to benefit from revascularization (bypass surgery to restore blood to a portion of the heart). This is referred to as a mismatch pattern (i.e., low blood flow with high glucose metabolism).

View larger version (30K): [in this window] [in a new window]   FIGURE 20. Case example, myocardial viability.

Key Management Issues.

• Determine whether patients with ischemic heart disease and symptoms of congestive heart failure are best treated with coronary artery bypass surgery, cardiac transplantation, or conservative medical therapy
  

Summary of Evidence for FDG PET in Myocardial Viability Assessment.
Myocardial viability studies with FDG PET should be performed in patients with ischemic heart disease and impaired left ventricular function who are potential candidates for coronary revascularization (Table 21).

	NEUROLOGICAL APPLICATIONS

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
Dementia Work-Up

Disease Background.
Dementia is defined as loss of memory and at least one other area of complex behavior sufficient to interfere with day-to-day function. The magnitude of the problem is increasing, and it is estimated that 5% of the population older than 65 y and up to 25% of the population older than 80 y has some form of dementia. Causes of dementia include degenerative changes (e.g., Alzheimer’s disease, Pick’s disease, Parkinson’s disease, Huntington’s disease), vascular insufficiency, trauma, endocrine changes, and other causes. Metabolic changes in the brain have been shown to precede structural changes by at least 5 y. Treatment for the degenerative forms of dementia, such as Alzheimer’s, is improving with the use of cholinesterase inhibitors and treatment options continue to grow. The diagnosis of early Alzheimer’s disease and its differential diagnosis from other organic dementias or the benign effects of aging remain clinically difficult today. PET with FDG has been shown to provide an accurate and positive differential diagnosis of Alzheimer’s and of other forms of organic dementias. In some ways, the diagnosis of dementia is similar to that for cancer in the separation of benign from malignant disease. In the case of dementia, it is the separation of benign from organic degenerative disease.

Case Example.
A 67-y-old man presented with a 3-y history of progressive loss of memory and day-to-day function and a clinical diagnosis of possible Alzheimer’s. A brain MR image showed no anatomic indications of disease. An FDG PET scan was ordered to evaluate for possible Alzheimer’s disease. Shown in the left column in Figure 21 is a normal FDG PET scan from a 64-y-old man. In the right column is the FDG PET scan from the patient in this case. Two representative slices are shown from each individual. The right column clearly shows low FDG metabolism in the back portion of the brain (arrows) in the parietal and temporal regions. This hypometabolism pattern is consistent with Alzheimer’s disease.

View larger version (68K): [in this window] [in a new window]   FIGURE 21. Case example, dementia.

Key Management Issues.

• Early diagnosis of dementia versus benign memory loss
  
• Differential diagnosis of dementia from frontotemporal disease, diffuse Lewy bodies, or cerebrovascular diseases
  
• Differentiation from pseudodementia/depression (This is a dementia-like state that is caused by depression and not Alzheimer’s disease.)
  

Summary of Evidence for FDG PET in Dementia Work-Up.
Primary neurodegeneration is the most common process underlying dementia, and Alzheimer’s disease alone accounts for approximately two-thirds of cases. Regional cerebral metabolic patterns reflect pathophysiologic changes in brain that will lead to Alzheimer’s disease, even before they give rise to symptoms. In addition to the diagnostic value FDG PET may have in evaluation of dementia, it can also serve as a prognostic tool to determine the likelihood of deterioration of mental status during the years after scanning, thereby facilitating planning by the patient and family members. Although results have varied, depending in part on the severity and diagnostic mix of patients, nearly all studies designed to assess the accuracy of FDG PET in the diagnosis of dementia have found sensitivity for Alzheimer’s disease to be >90%, with specificity typically approximating 75% (range, 67%–97%). Meeting the challenge of accurately identifying minimally affected patients to allow them to reap the greatest potential therapeutic benefits requires making the diagnosis with a high degree of sensitivity and overall accuracy at the earliest possible stage of disease. The consistently high sensitivity of FDG PET in patients with even mild impairment makes it well suited for assisting with that task (Table 22).

Disease Background.
Epilepsy is a common condition, with a prevalence in the population of about 1 in 200 people. Several abnormalities within the brain can lead to abnormal "synchronous firing" of neurons, causing a seizure. Depending on which part of the brain is epileptogenic, seizures will have different outward appearances. In a grand mal seizure, all extremities move as a result of abnormal neuronal firing, which spreads within the brain to cause a diffuse motor seizure. Imaging of all types helps to locate abnormalities within the brain, and, when coupled with electroencephalography (EEG, scalp electrical signal monitoring), can help to manage epilepsy patients. Many patients can be controlled well on medications. Patients who have seizures despite having tried several medications are referred to as patients with intractable seizures. In these patients, identifying the source of the seizure within the brain often can lead to surgery that can stop or reduce the seizures. Imaging, including FDG PET, can play an important role in determining whether a patient is a candidate to be operated on for seizure control. The alternative (invasive electronic monitoring) requires putting electrodes into the brain parenchyma or meninges, with attending morbidity and mortality.

Case Example.
An 11-y-old boy, diagnosed with epilepsy at age 7, had been treated with medications for 4 y. During the last year, he had continued to have seizures, even with a change in antiseizure medications. An FDG PET scan was ordered to evaluate for the possible source of the seizure. MRI showed no structural abnormality. The FDG PET scan (Fig. 22) showed moderate-to-severe hypometabolism (lower than normal glucose utilization) in the right parietal, posterior, frontal, occipital, and temporal lobes (arrows) in the interictal period (i.e., between seizures).

View larger version (70K): [in this window] [in a new window]   FIGURE 22. Case example, seizure.

Key Management Issues.

• Diagnosis of partial epilepsy (MRI negative)
  
• Localization of seizure focus
  
• Prediction of surgical outcome (prognosis)
  

Summary of Evidence for FDG PET in Seizure Work-Up.
In patients who have medically intractable epilepsy, neurosurgery to resect epileptogenic foci can decrease or eliminate seizure episodes and reduce neurologic impairment resulting from recurrent seizures and/or high doses of anticonvulsants. Patients with complex partial seizures, particularly those who have EEG evidence of a temporal lobe focus but inconclusive findings on MRI, often are referred for functional brain imaging to assess interictal metabolism. PET with FDG can identify epileptogenic zones through localization of hypometabolic brain tissue interictally. Interictal FDG PET has been demonstrated to be as useful for presurgical planning in most patients with temporal lobe epilepsy as the more logistically cumbersome ictal SPECT or more invasive EEG monitoring with depth electrodes. Patients with unilateral foci of hypometabolism identified by PET have been found in numerous studies to have a high likelihood of benefiting from neurosurgery, regardless of whether invasive electrode monitoring is also undertaken. Patients can thus be saved risks and costs otherwise incurred with invasive monitoring. Further study is needed to define more specifically the role of depth electrodes and surgical therapy in patients with findings of bilateral hypometabolism (Table 23).

	SUMMARY

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

	APPENDIX A. LITERATURE SEARCH CRITERIA AND DATA ANALYSIS METHODS

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
Literature Search Criteria
The literature search was performed using the databases Medline/Healthstar 1993–2000 and Biosis Previews 1993–2000 for articles and abstracts published from January 1993–June 2000. All key word combinations, including FDG PET, PET, and specific oncologic, neurologic, and cardiac applications were searched. Printed copies of The Journal of Clinical Positron Imaging (1998–2000) and The Journal of Nuclear Medicine abstracts (1996–2000) also were used. Only articles/abstracts in English were used, with the exception of a few English abstracts of non-English-language articles that provided complete information. Both dedicated PET and newer low-cost PET technology (for example, coincidence imaging) studies were included.

The only exceptions to our search time period occurred in the neurological and cardiac application categories. Specifically for myocardial applications, the Medline search extended back to 1986, with a focus on literature assessing viable myocardium. For dementia and seizure workup, the Medline search extended back to 1980, with respective foci on literature assessing accuracy in diagnosing individual patients with dementia and on literature assessing PET performance with respect to evaluating potential candidates for neurosurgery.

All literature that was not clear with respect to methods and/or reporting was excluded. Furthermore, any article/abstract that reported on a study with five or fewer individuals also was excluded. A total of 775 articles/abstracts were retrieved from the literature for our review. Approximately 8 articles could not be obtained from interlibrary requests to outside libraries. The data analysis used 473 unique articles/abstracts (specifically 151 abstracts and 322 articles), and 302 were excluded as per the inclusion/exclusion criteria. The spreadsheets listed a total of 561 article/abstract entries, of which 17 were repeated across several spreadsheets to which they were applicable and 71 were repeated within spreadsheets in multiple applications.

Inclusion Criteria.
(1) Abstracts and articles reporting data within which sensitivity (sens), specificity (spec), positive predictive value (ppv), negative predictive value (npv), accuracy (acc), and management change (mgmt) values were either partially or fully listed or could be partially or fully derived for FDG PET imaging in the 22 different oncologic areas, cardiac viability area, and dementia and seizure work-up areas. In addition, some studies (e.g., seizure) were listed with FDG PET contributions to clinical issues without accompanying accuracy data. Only data with stated or derived total patient studies or total lesions were incorporated into the weighted averages. In those instances in which CT data were found in the PET literature satisfying the inclusion criteria, these were also listed.

(2) Oncologic studies drawn from the period January 1993–June 2000; dementia and seizure studies from January 1980–June 2000; and cardiac studies from January 1986–June 2000.

(3) Response-to-treatment articles were included in the spreadsheets where a 2 x 2 table could be created from the reported data for: responders/nonresponders versus increased FDG/decreased FDG. In those instances in which a 2 x 2 table could not be formulated, the article was excluded.

Note that three articles were also included that provided no numerical information about FDG PET accuracy but had some useful features, which are described in the comments field. These articles, therefore, have no bearing on the weighted averages summarizing all the literature data. These studies by Bischoff et al. (46), Holthoff et al. (197), and Rozental et al. (354) were all part of the monitoring response application.

Exclusion Criteria.
(1) Case reports, review/tutorial articles, and studies with 5 or fewer patients.

(2) Articles not in English. However, abstracts in English of articles not in English but with relevant information were included.

Data Analysis
Data analysis was performed using simple weighted averages. Therefore, studies with more patients were weighted more than studies with fewer patients to arrive at estimates of the sensitivity, specificity, and, when possible, management changes. Weighting is the easiest method to use on such a large number of studies, each of which may or may not present a full 2 x 2 table of outcomes. No attempt was made to perform a formal meta-analysis.

In instances in which articles and abstracts included data for multiple categories (e.g., diagnosis/staging/recurrence), the entire article entry was listed in each of the three individual categories (diagnosis, staging, and recurrence) to preserve the entirety of a study’s reporting and to represent that study’s contribution to data for that category for both this report and possible future analyses that might be looking for all references including data for a given category (e.g., specifically for recurrence.) Only data relevant to a specific category was used in the weighted average for that category (e.g., in calculating the weighted average in the recurrence category, only the recurrence portion of the article’s data was used, even though data for diagnosis also may have been listed).

The number in the total patient studies column sometimes exceeded that in the total number of patients column for a given entry line (e.g., in instances in which patients may have had multiple FDG PET scans). For each line entry of data, the total patient studies or total lesions were listed upon which the 2 x 2 table was based for calculating a given line of data (e.g., if 58 patients had 62 scans from which the true positive (TP), true negative (TN), false positive (FP), and false negative (FN) values were counted, 62 was listed for total patient studies).

In those instances in which articles/abstracts had data broken down for various reported subgroups (e.g., mediastinal and hilar lymph nodes or lymph nodes <1 cm), total patient studies for each subgroup would be listed (as explained above), but often these subgroups would have overlapping patients. In terms of the data analysis, when a given study provided overall values in addition to listing various subgroup values, the overall value was used in the weighted average. When an overall value was not listed, the subgroup data was weighted in by the total patient studies value from which it was generated (or by total lesions, if listed by lesions). The only exceptions occurred in the lung cancer spreadsheet/staging section in the four articles by Baum et al. (36), Tatsumi et al. (424), Ryu et al. (356), and Marom et al. (290). When these studies reported subgroup values for the full patient study count multiple times, the subgroup values were averaged and weighted into the weighted average formula by the total patient studies for one group only.

	APPENDIX B. DATA ANALYSIS SUMMARY

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
Because the default analysis (analysis 1) of our 22 spreadsheets listed all the literature values used that included multiple listings of abstracts/articles both within spreadsheets (e.g., both in the diagnosis/staging and staging applications of a particular cancer) and across spreadsheets, some overlapping of patient studies occurred. To analyze the effects of listing the broad view of the literature values used we performed 5 additional data analyses to study the effects on PET sens/spec/acc by selecting out certain studies according to the following criteria:

(1) Analysis 1 (default analysis): Included all literature used that had some overlap of total patient studies within and across spreadsheets.

(2) Analysis 2: Used data from only those studies that reported jointly the sensitivity and specificity values for PET and PET accuracy values that included one other PET statistical ratio column (e.g., reported PET accuracy and also PET sensitivity).

(3) Analysis 3: Repeated the default analysis, including data from only full research articles. All abstracts were specifically excluded.

(4) Analysis 4: Repeated analysis 2, including data from only full research articles. All abstracts were excluded.

(5) Analysis 5: Pooled sens/spec/acc values for PET across all available studies that provided TP/TN/FP/FN values for each cancer and for all cancers together. This is a formal pooling analysis, using data from each study to construct a large 2 x 2 table. Note that all four cells (TP/TN/FP/FN) must be available, that is, information for patients both with and without disease is required. Therefore, some studies used in some of the weighted averaging subanalysis formulations (e.g., reporting sens only) could not be included in the pooling subanalysis, and thus slight discrepancies exist between the article subsets used in the weighted averages and those used in the pooling.

(6) Analysis 6: Repeated the default analysis excluding all data from nondedicated PET machines (e.g., coincidence imaging).

Results are provided in Table 25.

	APPENDIX C. ABBREVIATIONS LEGEND

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 
Abdom: abdominal
Abst: abstract
Acc: accuracy
Activ: activity
Addit: additional
Adenocarc: adenocarcinoma
Adjuv: adjuvant
Adrenalect: adrenalectomy
Adv: advanced
AFP: serum alpha-fetoprotein level
AIDS: acquired immunodeficiency syndrome
ALNDs: axillary lymph node dissections
Amen: amenable
Amput: amputations
Anat: anatomical
Andro: androgen
Antibod: antibodies
Antiestr: antiestrogen
Art: article
Aspir: aspirate
Assessmt: assessment
Asymp: asymptomatic
Autop: autopsy
Av: average
Avdmajsurg: avoid major surgery
BCNU: carmustine
Behav: behavioural
Biochem: biochemical
Biop: biopsy
Bne: bone
BPH: benign prostatic hyperplasia
Br: brain
Brst: breast
BS: bone scintigraphy
BTH: bilateral temporal hypometabolism
B/w: between
C: calcitonin
Ca: cancer
Calcit: calcitonin
Calcs: calculates
Cam: camera
Carcin: carcinoma
Cathet: catheterization
CDM: conventional diagnostic methods
CEA: carcino-embryonic antigen
Cerv: cervical
Chem: chemistry
Chemo: chemotherapy
Chemohormonother: chemohormonotherapy
Chemoradio: chemoradiotherapy
Chge: change
CHOL: 11C choline
Cholang: cholangio-pancreaticography
CI: conventional imaging
Classif: classification
Clin: clinical
Clinstge: clinical stage
Cm: centimeter
Cnfrm: confirmation
CNS: central nervous system
CoDe-PET: coincidence detection PET
Cognit: cognitive
Colonosc: colonoscopy
Compar: comparison
Concom: concomitant
Concord: concordance
Conn: connective
Cont: continued
Contrad: contradictory
Conv: conventional
Corr: correctly
Correl: correlation
CR: complete response
Craniot: craniotomy
Crse: course
CT: computed tomography
CUP: cancer of unknown primary
Cur: curative
CYT-356: capromab pendetide
Cytol: cytology
Cytopath: cytopathology
DAR: differential absorption ratio
Decis: decision
Decr: decrease
DedPET: dedicated PET
Def: definite
Degen: degenerative
Dem: dementia
Detect: detect
Diff: different
Differen: differentiated
Dimens: dimensions
Dis: disease
Discrep: discrepancy
Dissect: dissection
Dissem: disseminated
Dist: distant
Ds: days
DUR: dose uptake ratio
Dwnstge: downstage
Dx: diagnosis
Ea: each
EEG: electroencephalographic
E.g.: for example
Elev: elevation
Endos: endosonography
Endosc: endoscopic examination
Entero: enteroclysis
Epil: epilepsy
Epilept: epileptogenic
Equiv: equivocal
ER+: biopsy-proved estrogen receptor-positive
Esoph: esophageal
Eval: evaluate
Evid: evidence
Ex: exam
Excis: excisional
Exp: experience
Explor: exploratory
Ext: extension
Extrathor: extrathoracic
Fav: favorable
Fd: found
FDG: 2-[F-18]Fluoro-2-Deoxy-D-Glucose
Fm: from
FN: false negative
Fn: function
FNA: fine-needle aspiration
FNAB: fine needle aspiration biopsy
FP: false positive
Ga: gallium
Gastro: gastroesophageal
Gastros: gastroscopy
GCI: gamma camera coincidence imaging
Gde: grade
Gluc: glucose
Gp: group
GRD: gross residual disease
Gynecol: gynecological
H&N: head and neck
HCC: hepatocellular carcinoma
HD: hodgkin’s disease
Hep: hepatic
Hepatocell: hepatocellular
Hi: high
Hippocamp: hippocampal
Hist: history
Histol: histology
Histopath: histopathology
Horm: hormone
Hypertherm: hyperthermic
Hypometab: hypometabolic
Hypopharyng: hypopharyngeal
Ident: identify
Imag: imaging
IMLN: internal mammary lymph node
Immed: immediate
Imprvemt: improvement
IMT: 123I-Iodo-alpha-methyltyrosine
Inconclus: inconclusive
Incorr: incorrectly
Incr: increased
Indeterm: indeterminate
Indic: indicative
Individ: individual
Info: information
Init: initiate; initial
Insuffic: insufficient
Interict: interictal
Intracran: intracranial
Intract: intractable
Involv: involvement
IORT: intraoperative radiation therapy
Irrad: irradiated
IS: immunoscintigraphy
Isol: isolated
Kn: known
Lapar: laporatory
Laparat: laparotomy
Laryng: laryngeal
Lateraliz: lateralization
Les: lesion
Lft: left
LN: lymph node
Lo: low
Loc: local
Locat: location
Locoreg: locoregional
Lowabd: lower abdomen
LT: long term
Lumpect: lumpectomy
Lymphad: lymphadenectomy
Majdwn: major downstaging
Majmgmt: major management
Majupstg: major upstaging
Malig: malignancy
MALT: mucosa-associated lymphoid tissue
Mar: marrow
Mastect: mastectomy
Meas: measurable
Mediast: mediastinal
Mediastinos: mediastinoscopy
Melan: melanoma
MET: 11-Cmethionine
Met: metastatic
Metab: metabolism
Mets: metastases
Mgmt: management
MH: M. Hodgkin
MIBG: metaiodo-benzylguanidine
MIBI: 99mTc-Methoxyisobutylisonitrile
MI-CPS: medically intractable complex partial seizures
Mindwn: minor downstaging
Minmgmt: minor management
Minupstg: minor upstaging
Misc: miscellaneous
MM: mammography
Mo: month
Mod: moderately
Modals: modalities
Mon: monitor
Morphol: morphologic
MR: magnetic resonance
MRD: minimal residual disease
MRI: magnetic resonance imaging
MTC: medullary thyroid cancer
N: total number of patient studies or lesions
N staging: nodal staging
NC: no change
ND: new disease
Necros: necrosis
NED: no evidence of disease
Neg: negative
Neurodeg: neurodegenerative
NHL: non-Hodgkin’s lymphoma
Nk: neck
No: number
Nochge: no change
Noneupstg: none upstaged
NPV: negative predictive value
Nr: near
Nsclc: non-small cell lung cancer
Nt: not
Observ: observation
Occ: occupying
Oper: operable
OPET: other PET
Ophthal: opthalmologic
Osteo: osteomyelitis
Otolaryn: otolaryngologic
Ovar: ovarian
Overstgd: overstaged
P53: p53 protein expression of HCC
Pancr: pancreatic
Papill: papillary
Paramalig: paramalignant
Part: partial
Pathol: pathology
Pblms: problems
Pca: prostate cancer
PCS: positron coincidence scintigraphy
PD: progressed disease
Pelv: pelvic
Perfsurg: perform surgery
Perfus: perfusion
Persist: persistent
PET: positron emission tomography
Phys: physical
Polychemo: polychemotherapy
Poor: poorly
Potent: potentially
PPV: positive predictive value
PR: partial response
Preop: preoperative
Prim: primary
Prob: probably
Proced: procedure
Progress: progressing metastases; progression
Prolif: proliferative
Prost: prostate
PSA: prostate specific antigen
Pt: patient
Pt gp: patient group
Pts: patients
Pulm: pulmonary
RA: research article
Rad: radiation
Rad lymphad: radical lymphadenectomy
Radiog: radiography; radiographic
Radiol: radiological
Recur: recurring
Recurr: recurrence
Ref: reference
Refrac: refractory
Relap: relapsed
Resect: resectable
Resid: residual
Resis: resistant
Restage: restaging
Retroper: retroperitoneal
Retrosp: retrospective
Rev: review
RIT: radioimmunotherapy
RNB: radionuclide bone scintigraphy
Rpts: reports
Rspnse: response
Scint: scintigraphy
Sclc: small cell lung cancer
Scn: scan
SEEG: stereo-EEG
Sens: sensitivity
Ser: serial
Signif: significantly
Simult: simultaneously
Sites: lesion sites
Sl: slight
Smplg: sampling
SNB: sentinel node biopsy
Sonog: sonography
Sp: space
Spdsht: spreadsheet
Spec: specificity
SPECT: single-photon emission CT
SPET: single photon emission tomography
SPN: solitary pulmonary nodule
S.t.: short-term
Std: standard
Stereo biop: stereotactic biopsy
Stg: stage
Strat: strategy
STS: soft tissue sarcomas
Subclin: subclinical
Subgps: subgroups
SUR: standardized uptake ratio
Surf: surface
Surg: surgery
Susp: suspected
Suspic: suspicious
SUV: standardized uptake values
Symp: symptom
Sys: system
Sz: seizure
TCB: trucut biopsy
Temp: temporal
Tg: thyroglobulin
Theor: theoretical
Ther: therapy
Therap: therapeutic
Thor: thoracic
Thorac: thoracotomy
Thyrd: thyroid
Thyroglob: thyroglobulin
Tiss: tissue
T: L ratio:tumor-to-normal liver ratio
TLE: temporal lobe epilepsy
TN: true negative
Tot: total
TP: true positive
Trtmt: treatment
TTNA: transthoracic needle aspiration
Tum: tumor
Ultim: ultimately
Understgd: understaged
Unil: unilateral
Unk Prim: unknown primary
Unnecess: unnecessary
Upstge: upstage
Uptke: uptake
US: ultrasonography
Uter: uterine
UTH: unilateral temporal hypometabolism
Util: utilization
Vasc: vascular
Vert: vertebral
Vs: versus
W: with
WB: whole body
WBS: whole-body scintigraphy
Wd: would
With: withdrawal
Wks: weeks
Wt: weight
WW: watchful waiting
Y: year
131-I: 131-Iodine
2x2: two by two table of true/false positive values and true/false negative values
18F-FDG: 18F-fluorodeoxyglucose
201Tl SPET: 201Tl single photon emission tomography
201Tl SPECT: 201 Tl chloride single-photon emission CT
#: number
+: positive
-: negative
<: less than
>: greater than

	FOOTNOTES

 
Received Dec. 27, 2000; accepted Dec. 27, 2000.

For correspondence or reprints contact: Sanjiv S. Gambhir, MD, PhD, UCLA School of Medicine, 700 Westwood Plaza, B3-399A BRI, Box 951770, Los Angeles, CA 90095-1770.

	REFERENCES

TOP INTRODUCTION INTERPRETING SPREADSHEETS IN... ONCOLOGIC APPLICATIONS CARDIAC APPLICATIONS NEUROLOGICAL APPLICATIONS SUMMARY APPENDIX A. LITERATURE SEARCH... APPENDIX B. DATA ANALYSIS... APPENDIX C. ABBREVIATIONS LEGEND REFERENCES

 

1. AAssar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999;210:177–181.[Abstract/Free Full Text]
2. Abdel-Nabi H, Abou-Zied MM, Doerr RJ. Preoperative evaluation of patients with suspected liver metastases with positron emission tomography with F-18 FDG [abstract]. J Nucl Med 1999;40:241P.
3. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755–760.[Abstract/Free Full Text]
4. Achten E, Santens P, Boon P, et al. Single-voxel proton MR spectroscopy and positron emission tomography for lateralization of refractory temporal lobe epilepsy. Am J Neuroradiol 1998;19:1–8.[Abstract]
5. Acland KM, O’Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000;42:606–611.[Medline]
6. Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255–1260.[Medline]
7. Adler L, Crowe J, al-Kaisi N, Sunshine J. Evaluation of breast masses and axillary lymph nodes with [F-18] 2 deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743–750.[Abstract/Free Full Text]
8. Adler L, Faulhaber P, Schnur K, Al-Kasai N, Shenk R. Axillary lymph node metastases: screening with [F-18]2 deoxy-2-D-glucose (FDG) PET. Radiology 1997;203:323–327.[Abstract/Free Full Text]
9. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993;3:195–200.[Medline]
10. Akimura T, Yeh HS, Mantil JC, Privitera MD, Gartner M, Tomsick TA. Cerebral metabolism of the remote area after epilepsy surgery. Neurol Medico-Chirurg 1999;39:16–27.
11. Al-Sugair AS, Coleman RE. Relative diagnostic efficacy of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer [abstract]. J Nucl Med 1999;40:20P.
12. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999;53:808–811.[Medline]
13. Albes JM, Lietzenmayer R, Schott U, Schülen E, Wehrmann M, Ziemer G. Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thoracic Cardiovasc Surgeon 1999;47:42–47.
14. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010–1015.[Abstract/Free Full Text]
15. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998;383:160–163.[Medline]
16. Amthauer H, Hosten N, Mueller-York A, et al. Whole body FDG-PET before laser-induced thermo-therapy (LITT) in patients with hepatic metastases of colorectal cancer [abstract]. J Nucl Med 2000;41:35P.
17. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135–141.[Abstract/Free Full Text]
18. Austin JR, Wong FC, Kim EE. Positron emission tomography in the detection of residual laryngeal carcinoma. Otolaryngol Head Neck Surg 1995;113:404–407.[Medline]
19. Avril N, Dose J, Jänicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848–1857.[Abstract/Free Full Text]
20. Avril N, Schelling M, Naehrig J, et al. Monitoring primary chemotherapy in advanced breast cancer using FDG-PET [abstract]. J Nucl Med 2000;41:112P–113P.
21. Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE. Positron emission tomography: introduction of a new imaging technique for urological tumors and initial clinical results [in German]. Urologe Ausgabe A 1995;34:138–142.
22. Bachor R, Kotzerke J, Gottfried HW, Braendle E, Reske SN, Hautmann R. Positron emission tomography (PET) for diagnosis of renal cell carcinoma (RCC) [in German]. Urologe Ausgabe A 1996;35:146–150.
23. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging for urinary bladder carcinoma with positron emission tomography (PET) [in German]. Urologe Ausgabe A 1999;38:46–50.
24. Bader JB, Samnick S, Schaefer A, et al. Contribution of nuclear medicine to the diagnosis of recurrent brain tumors and cerebral radionecrosis [in German]. Radiologe 1998;38:924–929.[Medline]
25. Bader JB, Siebert S, Schaefer A, et al. Diagnostic efficiency in the detection of brain tumor recurrence at follow-up by 123I alpha-methyltyrosine-SPECT and 18FDG-PET [abstract]. J Nucl Med 1997;38:239P.
26. Baehre MH, Markert U, Meller B, et al. Oncologic information provided by immunoscintigraphy with 99mTc Fab’ fragments compared with (18F)FDG PET in colorectal cancer [abstract]. J Nucl Med 2000;41:141P.
27. Baer F, Voth E, Deutsch H. Predictive value of low-dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60–69.[Abstract]
28. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncologica (Stockholm) 1999;38:799–804.
29. Bangerter M, Moog F, Buchman I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography FDG-PET for accurate staging of Hodgkin’s disease. Ann Oncol 1998;9:1117–1122.[Abstract/Free Full Text]
30. Bares R, Dohmen B, Cremerius U, Fass J, Teusch M, Buell U. Results of positron emission tomography with fluorine-18-labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma [in German]. Radiologe 1996;36:435–440.[Medline]
31. Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron emission tomography. Horm Metab Res. 1993;27(suppl):56–58.
32. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79–86.[Abstract/Free Full Text]
33. Bares R, Klever P, Hellwig D, et al. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993;14:596–601.[Medline]
34. Barrington SF, Koutroumanidis M, Agathonikou A, et al. Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 1998;39:753–766.[Medline]
35. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931–938.[Abstract/Free Full Text]
36. Baum RP, Schmuecking M, Plichta K, et al. Staging of non-small cell lung cancer (NSCLC): is PET really clinically important or just a research tool [abstract]? J Nucl Med 2000;41:293P–294P.
37. Beets G, Pennickx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer. Br J. Surg. 1994;81:1666–1670.[Medline]
38. Bellon JR, Mankoff DA, Eubank WB, et al. Evaluation of the internal mammary (IM) lymph node (LN) chain by PET in locally advanced breast cancer (LABC) [abstract]. J Nucl Med 2000;41:145P.
39. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 1996;116:332–335.[Medline]
40. Bender H, Bangard N, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999;18:87–91.[Medline]
41. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17:1687–1692.[Medline]
42. Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994;16:340–346.[Medline]
43. Bernstein V, Jones A, Mankoff DA, Davis N. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer [abstract]. J Nucl Med 2000;41:289P.
44. Berry WAC, Molloy PT, Alavi A, Vaughan SN. Neuroimaging in the evaluation of suspected brain tumor recurrence in the pediatric population, the critical role of fluorodeoxyglucose (18-FDG) positron emission tomography (PET) studies [abstract]. J Nucl Med 1997;38:12P–13P.
45. Beuthien-Baumann B, Bredow J, Eckelt U, Franke WG, Hlawitschka M, Neise E. Diagnostic value of 18F-FDG PET in detecting carcinoma of the oral mucosa in comparison with MRI, CT, and ultrasound (US) [abstract]. J Nucl Med. 2000;41:301P.
46. Bischoff HG, Knopp MV, Rimac A, Manegold C, Drings P, Van Kaick G. Chemotherapy response monitoring with FDG positron emission tomography of patients with small cell lung cancer [abstract]. Ann Hematol 1996;73:A99.
47. Bleckmann C, Dose J, Bohuslavizki KH, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer [see comments]. J Nucl Med 1999;40:2021–2024.[Abstract/Free Full Text]
48. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma [see comments]. Arch Dermatol 1995;131:1394–1398.[Abstract/Free Full Text]
49. Block M, Patterson G, Sundaresan R, et al. Improvement in staging of esophageal cancer with addition of positron emission tomography. Ann Thorac Surg 1997;64:770–776.[Abstract/Free Full Text]
50. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993;114:728–735.[Medline]
51. Blum DE, Ehsan T, Dungan D, Karis JP, Fisher RS. Bilateral temporal hypometabolism in epilepsy. Epilepsia 1998;39:651–659.[Medline]
52. Bohdiewicz PJ, Scott GC, Juni JE, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations. Clin Nucl Med. 1995;20:230–236.[Medline]
53. Bohuslavizki KH, de Wit M, Buchert R, et al. Post-treatment 18F-FDG-PET as predictor for disease-free survival in Hodgkin’s lymphoma [abstract]. J Nucl Med 2000;41:275P.
54. Bohuslavizki KH, Klutmann S, Kröger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816–822.[Abstract/Free Full Text]
55. Bohuslavizki KH, Klutmann S, Neuber K, et al. Correlation of 18F FDG-PET and histological findings in patients with malignant melanoma [abstract]. J Nucl Med 2000;41:302P.
56. Bombardieri E, Crippa F, Agresti R, et al. FDG-PET in the assessment of axillary metastases in breast cancer. Clinical application and economic implications [abstract]. J Nucl Med 1998;39:254P.
57. Bongers V, Terhaard CJ, van Isselt JW, Hordijk GJ, van Rijk PP. Dual-head FDG-PET for the detection of recurrent laryngeal cancer compared with histopathological biopsy results and minimally 1-year clinical follow-up [abstract]. J Nucl Med 2000;41:287P.
58. Böni R, Böni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556–562.[Medline]
59. Both SA, Schaeffer U, Schlenger KH, et al. 18F FDG-PET in clinical assessment of primary uterine cervical carcinoma: detection and correlation with tumor oxygen partial pressure [abstract]. J Nucl Med 2000;41:116P.
60. Braams J, Pruim J, Freling N, et al. Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211–216.[Abstract/Free Full Text]
61. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997;26:112–115.[Medline]
62. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Euro J Nucl Med 2000;27:490–496.[Medline]
63. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376–1380.[Abstract]
64. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410–414.[Abstract]
65. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560–2564.[Abstract]
66. Cambier JPR, Flamen P, Maes A, Van Cutsem E, Lerut T, Mortelmans L. FDG-PET for staging recurrent esophageal cancer (EC) [abstract]. J Nucl Med 2000;41:32P.
67. Caputo GR, Budinger T, Price D, Schreck C, Hawkins R. Evaluation of prostate cancer using high-resolution FDG PET imaging [abstract]. J Nucl Med 1997;38:128P.
68. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–3346.[Abstract/Free Full Text]
69. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331–338.[Medline]
70. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:455–464.[Medline]
71. Cheon G, Chung J, So Y, et al. Diagnostic accuracy of F-18 FDG-PET in the assessment of post-therapeutic recurrence of head and neck cancer. Clin Positron Imaging 1999;2:197–204.[Medline]
72. Chierichetti F, Rubello D, Pedrazzoli S, et al. FDG PET role in differential diagnosis of pancreatic and peri-pancreatic masses [abstract]. J Nucl Med 1997;38:51P.
73. Chin R Jr, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090–2096.[Abstract]
74. Chisin R, Klein M, Freedman N, et al. PET and lymphoscintigraphic evaluation of malignant melanomas: the Hadassah Hospital experience [abstract]. Clin Positron Imaging 1998;1:252.[Medline]
75. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808–815.[Abstract/Free Full Text]
76. Chugani HT, Shewmon DA, Peacock WJ, Shields WD, Mazziotta JC, Phelps ME. Surgical treatment of intractable neonatal-onset seizures: the role of positron emission tomography. Neurology 1988;38:1178–1188.[Abstract/Free Full Text]
77. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan [see comments]. J Nucl Med 1999;40:986–992.[Abstract/Free Full Text]
78. Collins BT, Gardner LJ, Verma AK, Lowe VJ, Dunphy FR, Boyd JH. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol 1998;42:1325–1329.[Medline]
79. Conti P, Durski J, Bacqai F, Grafton S, Singer P. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797–804.[Medline]
80. Cortes-Blanco A, Meyer PT, Martinez-Lazaro R, Desiderio LM, Molloy PT, Alavi AA. Discrepant performance of FDG-PET and magnetic resonance imaging (MRI) and spectroscopy (MRS) for the detection of brain tumor recurrence between adults and children [abstract]. J Nucl Med 2000;41:225P.
81. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403–1406.[Medline]
82. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055–1063.[Medline]
83. Cremerius U, Wildberger H, Zimny M, Jaksy G, Gunther R, Buell U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900–904.[Medline]
84. Crespo-Jara AA, Garcia MJ, Gimenez M, et al. Skeletal metastases in lung cancer: accuracy of 18FDG-PET in correlation with bone scintigraphy [abstract]. J Nucl Med 1999;40:258P.
85. Crespo-Jara AA, Gimenez M, Villar LM, et al. Evaluation of adrenal masses in lung cancer using 18FDG PET. J Nucl Med 2000;41:293P.
86. Crippa F, Agresti R, Donne VD, et al. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan [in Italian]. Tumori 1997;83:542–543.[Medline]
87. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4–8.[Abstract/Free Full Text]
88. Crowe J, Adler L, Shenk R, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol. 1994;1:132–140.[Medline]
89. da Silva EA, Chugani DC, Muzik O, Chugani HT. Landau-Kleffner syndrome: metabolic abnormalities in temporal lobe are a common feature. J Child Neurol 1997;12:489–495.[Abstract/Free Full Text]
90. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325–329.[Medline]
91. De Reuck J, Santens P, Decoo D, et al. Positron emission tomographic study of late-onset cryptogenic symptomatic seizures. Clin Neurol Neurosurg 1995;97:208–212.[Medline]
92. De Winter F, Van de Wiele C, Vogelaers D, et al. FDG PET is highly accurate in the diagnosis of chronic osteomyelitis in the central skeleton [abstract]. J Nucl Med 2000;41:15P.
93. de Wit M, Bender H, Dohmen BM, et al. Germ cell tumor: staging with FDG-PET. Pilot phase of the German multicenter trial [abstract]. J Nucl Med 1999;40:256P.
94. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997;8(suppl 1):57–60.[Abstract/Free Full Text]
95. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51–56.[Medline]
96. Delbeke D, Lawrence SK, Abou-Khalil BW, Blumenkopf B, Kessler RM. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. Invest Radiol 1996;31:261–266.[Medline]
97. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510–516.[Abstract/Free Full Text]
98. Delbeke D, Morgan DS, Kovalsky E, et al. 18F-fluorodeoxyglucose imaging with positron emission tomography in the follow-up of patients with lymphoma [abstract]. J Nucl Med 2000;41:70P.
99. Delbeke D, Morgan DS, Kovalsky E, et al. 18F-fluorodeoxyglucose imaging with positron emission tomography for initial staging of Hodgkin’s disease and lymphoma [abstract]. J Nucl Med 2000;41:275P.
100. Delbeke D, Rose D, Chapman W, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784–1791.[Abstract/Free Full Text]
101. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201.[Abstract/Free Full Text]
102. Deshmukh A, Scott JA, Palmer EL, Hochberg FH, Gruber M, Fischman AJ. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 1996;21:720–725.[Medline]
103. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997–1002.[Abstract/Free Full Text]
104. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441–446.[Abstract/Free Full Text]
105. Di Martino E, Nowak B, Krombach GA, et al. Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET). Laryngo-Rhino-Otologie 2000;79:201–206.[Medline]
106. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342–1348.[Medline]
107. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998;37:12–17.[Medline]
108. Dimitrakopoulou-Strauss A, Heichel T, Lehner B, Strauss LG. Positron emission tomography (PET) with 18F-deoxyglucose (FDG) in tumors of the skeleton system [abstract]. J Nucl Med 2000;41:304P.
109. Dimitrakopoulou-Strauss A, Schwarzbach M, Willeke F, Strauss LG. PET with FDG in soft tissue sarcomas [abstract]. J Nucl Med 2000;41:303P.
110. Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434–442.[Medline]
111. Dittmann H, Dohmen BM, Soekler M, Kanz L, Bares R. Therapeutic relevance of FDG-PET in untreated Hodgkin’s disease and high-grade non-Hodgkin lymphoma [abstract]. J Nucl Med 2000;41:71P.
112. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130–140.[Abstract/Free Full Text]
113. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348–1352.[Abstract/Free Full Text]
114. Duncan JD, Moss SD, Bandy DJ, et al. Use of positron emission tomography for presurgical localization of eloquent brain areas in children with seizures. Pediatr Neurosurg 1997;26:144–156.[Medline]
115. Eigtved A, Andersson AP, Dahlstrm K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70–75.[Medline]
116. Engel J Jr, Henry TR, Risinger MW, et al. Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG. Neurology 1990;40:1670–1677.[Abstract/Free Full Text]
117. Ericson K, Kihlström L, Mogard J, et al. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irradiated brain metastases. Stereotact Funct Neurosurg 1996;66.(suppl 1):214–224.
118. Eubank WB, Mankoff DA, Shanley TJ, et al. Assessment of mediastinal lymph node metastasis in advanced breast cancer: comparison of FDG PET with CT [abstract]. J Nucl Med 1999;40:17P–18P.
119. Farber L, Benard F, Machtay M, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999;109:970–975.[Medline]
120. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468–1472.[Abstract/Free Full Text]
121. Fenchel S, Kotzerke J, Stöhr I, et al. Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F-18 fluorodeoxyglucose. Nuklearmedizin 1999;38:101–107.[Medline]
122. Ferrie CD, Maisey M, Cox T, et al. Focal abnormalities detected by 18FDG PET in epileptic encephalopathies [see comments]. Arch Dis Child 1996;75:102–107.[Abstract/Free Full Text]
123. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments]. J Clin Oncol 1996;14:700–708.[Abstract/Free Full Text]
124. Finke J, Buchmann I, Bares R, et al. (F-18)-FDG-PET in primary staging of malignant lymphoma: first results of a multicenter study [abstract]. J Nucl Med 1999;40:61P.
125. Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluoro-deoxy glucose in detecting residual/recurrent squamous cell carcinoma of the head and neck [see comments]. Am J Neuroradiol 1998;19:1189–1196.[Abstract]
126. Flamen P, Stroobants S, Dupont P, et al. Additional value of positron emission tomography (PET) with fluorodeoxyglucose (FDG) in recurrent colorectal cancer: a study in 103 patients [abstract]. J Nucl Med 1998;39:134P.
127. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894–901.[Abstract/Free Full Text]
128. Flanagan F, Dedashti F, Siegel B, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR 1997;168:417–424.[Abstract/Free Full Text]
129. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319–323.[Medline]
130. Fois A, Farnetani MA, Balestri P, et al. EEG, PET, SPET and MRI in intractable childhood epilepsies: possible surgical correlations. Child Nerv Syst 1995;11:672–678.[Medline]
131. Forster GJ, Kunkel M, Kutzner J, et al. Early monitoring of treatment response by (18F)FDG-PET in preoperatively irradiated advanced oral cancer [abstract]. J Nucl Med 2000;41:113P.
132. Franke C, Klapdor R, Meyerhoff K, Schauman M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999;19:2437–2442.[Medline]
133. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomoraphy. Gut 1995;36:771–777.[Abstract/Free Full Text]
134. Fröhlich A, Diederichs C, Staib L, Vogel J, Beger H, Reske S. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250–255.[Abstract/Free Full Text]
135. Fujii H, Yasuda S, Ide M, et al. The usefulness of breast cancer screening using 18F FDG PET [abstract]. J Nucl Med 2000;41:291P.
136. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998;39:1002–1007.[Abstract/Free Full Text]
137. Gamez C, Garcia-Velloso MJ, Villar LM, et al. 18F-FDG and 11C-methionine PET for evaluation of suspected recurrent colorectal cancer [abstract]. J Nucl Med 2000;41:141P.
138. Gauthier H, Levy E, Merlet P, Thirion P, Syrota A, Meignan M. High negative predictive value of FDG-PET for assessment of progressive disease in patients with soft tissue sarcoma [abstract]. J Nucl Med 1999;40:259P.
139. Gerber B, Vanoverschelde J, Bol A. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996;94:651–659.[Abstract/Free Full Text]
140. Gimenez M, Crespo-Jara AA, Villar L, et al. Preoperative and intraoperative uptake of 18FDG-PET in axillary metastases of breast cancer. A pathological correlation [abstract]. J Nucl Med 1999;40:138P.
141. Gliem I, Leutz M, Hellwig D, et al. Evaluation of malignancy-related pleural disease with FDG-positron emission tomography (PET) [abstract]. Eur Respir J 1998;12:392S.
142. Goldberg MA, Lee MJ, Fischman AJ, Mueller PR, Alpert NM, Thrall JH. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. RadioGraphics 1993;13:1047–1062.[Abstract/Free Full Text]
143. Grab D, Flock F, Stöhr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454–459.[Medline]
144. Greven KM, Keyes JW Jr, Williams DW III, McGuirt WF, Joyce WT III. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999;86:114–118.[Medline]
145. Greven KM, Williams DW III, Keyes JW Jr, et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994;29:841–845.[Medline]
146. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation [see comments]. Cancer 1994;74:1355–1359.[Medline]
147. Grigsby PW, Dehdashti F, Elbendary AA, et al. FDG-PET evaluation of primary carcinoma of the cervix. Gynecol Oncol 1999;72:457–458.
148. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420–1427.[Abstract/Free Full Text]
149. Gropler R, Geltman E, Sampathkurmaran K. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993;22:1587–1597.[Abstract]
150. Grünwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547–1552.[Medline]
151. Grünwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131I and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327–335.[Medline]
152. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312–319.[Medline]
153. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by (18F)FDG positron emission tomography (PET). Thorax 1997;52:438–441.[Abstract]
154. Gupta NC, Bishop HA. Long-term outcome of patients with indeterminate lung nodules following management based on PET-FDG results [abstract]. J Nucl Med 2000;41:76P.
155. Gupta NC, Bishop HA, Graeber GM. Incidence and characteristics of falsely positive and negative lymph node on PET and CT in lung cancer staging [abstract]. J Nucl Med 1999;40:57P.
156. Gupta NC, Graeber G, Rogers J, Koay T, Bishop H. Relative utility of PET-FDG and CT scanning in preoperative TNM staging of lung cancer patients [abstract]. J Nucl Med 1998;39:80P.
157. Gupta NC, Graeber GM, Bishop HA, Raylman RR. Improved pre-operative staging of primary lung cancer by PET-FDG imaging [abstract]. J Nucl Med 1997;38:243P–244P.
158. Gupta NC, Graeber GM, Bishop HA, Stephens TS. Comparative efficacy of FDG-PET in evaluation of small (less than 3 cm) and large (greater than 3 cm) pulmonary (PUL) and lymph node (LN) lesions [abstract]. J Nucl Med 1997;38:79P.
159. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET [see comments]. J Nucl Med 1996;37:943–948.[Abstract/Free Full Text]
160. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg 1999;230:202–206.[Medline]
161. Gupta NC, Tamim WZ, Bishop HA. Is there any incremental value of routine lymph node sampling using mediastinoscopy and/or thoracotomy or open biopsy for management of lung cancer patients following whole body PET [abstract]? J Nucl Med 2000;41:76P.
162. Gupta-Burt S, Marcus E, Coon J, et al. The role of positron-emission tomography (PET) in the assessment of pathologic response to neoadjuvant chemotherapy with doxorubicin and docetaxel in patients with locally advanced breast cancer [abstract]. Eur J Cancer 1999;35:S316.
163. Haase A, Lauer I, Meller B, Richter E, Baehre MH. Feasibility of detecting unknown primary tumors with gamma camera coincidence PET [abstract]. J Nucl Med 2000;41:296P.
164. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12–17.[Abstract/Free Full Text]
165. Haenggeli CA, Dulguerov P, Slosman D, et al. Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma [in German]. Schweiz Med Wochenschr. 2000;116.(suppl):8S–11S.
166. Hagberg RC, Segall GM, Stark P, Burdon TA, Pompili MF. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg 1997;12:92–97.[Abstract]
167. Hain SF, O’Doherty MJ, Huddart RA, Leslie MD, Timothy AR, Harper PG. The value of FDG-PET in recurrent testicular carcinoma [abstract]. J Nucl Med 1999;40:105P.
168. Hain SF, O’Doherty MJ, Leslie MD, Timothy AR. Staging of testicular carcinoma with FDG-PET [abstract]. J Nucl Med 1999;40:256P.
169. Hain SF, O’Doherty MJ, Lucas JD, Smith MA. Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma. Nucl Med Commun 1999;20:845–848.[Medline]
170. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880–885.[Medline]
171. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–995.[Abstract/Free Full Text]
172. Harms W, Bares R, Kamps H, Gronimus R, Boeckmann W, Jake G. Therapy control of metastatic testicular carcinoma with F18-DOG PET [abstract]. J Nucl Med 1995;36:198P.
173. Harrison J, Ali A, Bonomi P, Prinz R. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg 2000;66:432–437.[Medline]
174. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:704–713.[Medline]
175. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807–814.[Abstract/Free Full Text]
176. Heicappell R, Mueller-Mattheis V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-(18F)-2-deoxy-D-glucose. Eur Urol 1999;36:582–587.[Medline]
177. Heinz R, Ferris N, Lee EK, et al. MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy. Am J Neuroradiol 1994;15:1341–1348.[Abstract]
178. Helveston W, Gilmore R, Roper S, et al. Intractable temporal lobe epilepsy: comparison of positron emission tomography with qualitative and quantitative MR. Am J Neuroradiol 1996;17:1515–1521.[Abstract]
179. Henze M, Brix G, Knopp M, et al. Functional breast imaging: comparison of 18F-fluorodeoxyglucose (FDG) PET and pharmacokinetic MR mapping (DMRI) [abstract]. J Nucl Med 2000;41:290P.
180. Henze M, Mohammed A, Mier W, et al. Pretreatment studies of 18F-fluorodeoxyglucose (FDG), 123I-[alpha]-methlytyrosine (IMT) and 99mTc-sestamibi uptake in hypopharynx-larynx-carcinomas [abstract]. J Nucl Med. 2000;41:142P.
181. Herholz K, Perani D, Salmon E, et al. Comparability of FDG PET studies in probable Alzheimer’s disease. J Nucl Med 1993;34:1460–1466.[Abstract/Free Full Text]
182. Hicks RJ, Binns D, Kalff V, et al. The utility of flourine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for restaging of non-small cell lung cancer (NSCLC): Analysis of management change and survival in 63 consecutive patients [abstract]. J Nucl Med 2000;41:75P.
183. Higashi K, Nishikawa T, Seki H, et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9–15.[Abstract/Free Full Text]
184. Higashi K, Ueda Y, Kodama Y, et al. Comparison of 18F FDG PET and 201Tl SPECT in evaluation of pulmonary nodules [abstract]. J Nucl Med 2000;41:297P.
185. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999;40:1424–1433.[Abstract/Free Full Text]
186. Hoda S, Ardakani N, Hawkins RA. Significance of PET-FDG in comparison with 131I WBS and serum Tg in detection of recurrent and metastatic papillary thyroid carcinoma [abstract]. J Nucl Med 2000;41:312P.
187. Hoffman J, Welsh-Bohmer K, Hanson M, et al. FDG-PET imaging in pathologically verified dementia. J Nucl Med 2000;41:1920–1928.[Abstract/Free Full Text]
188. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567–575.[Abstract/Free Full Text]
189. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185–1189.[Abstract/Free Full Text]
190. Hoh C, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 1997;38:343–348.[Abstract/Free Full Text]
191. Hoh CK, Chap L, Glaspy JA, Bui S, Czernin J, Phelps ME. Prognostic value of whole body FDG PET in breast cancer patients undergoing chemotherapy [abstract]. J Nucl Med 1998;39:254P.
192. Hoh CK, Figlin RA, Belldegrun A, et al. Evaluation of renal cell carcinoma with whole body FDG PET [abstract]. J Nucl Med 1996;37:141P.
193. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17:582–589.[Medline]
194. Hoh CK, Rosen PJ, Belldegrun A, Moon DH, Maddahi J, Phelps ME. Quantitative and whole-body FDG PET in the evaluation of suramin therapy in patients with metastatic prostate cancer [abstract]. J Nucl Med 1996;37:267P.
195. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764–771.[Medline]
196. Holopainen IE, Lundbom NM, Metsähonkala EL, et al. Temporal lobe pathology in epilepsy: proton magnetic resonance spectroscopy and positron emission tomography study. Pediatr Neurol 1997;16:98–104.[Medline]
197. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993;72:1394–1403.[Medline]
198. Hölzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993;17:681–687.[Medline]
199. Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 1998;187:191–197.[Medline]
200. Hübner K, McDonald T, Niethammer J, Smith G, Gould H, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using (2-[18F]FDG). Gynecol Oncol 1993;51:197–204.[Medline]
201. Hübner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996;21:941–949.[Medline]
202. Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 1995;20:293–298.[Medline]
203. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26:1501–1509.[Medline]
204. Hwang KH, Park CH, Kim HC, Kim HS, Yoon SN, Kim S. Imaging of malignant lymphomas with 18F-FDG coincidence detection PET (CoDe-PET) [abstract]. J Nucl Med 2000;41:278P.
205. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194–199.[Medline]
206. Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385:129–134.[Medline]
207. Inagaki K, Morita T, Fujii K, Kosaka N, Hara T. Mediastinal lymph node staging in non-small cell lung cancer using PET with C-11 choline and F-18 FDG [abstract]. J Nucl Med 1999;40:59P–60P.
208. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345–352.[Abstract/Free Full Text]
209. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788–793.[Abstract/Free Full Text]
210. Inubushi M, Ishida Y, Fukuchi K, Fukushima K, Sasako K. Myocardial viability assessment using 18F FDG gated PET [abstract]. J Nucl Med 2000;41:157P.
211. Israel O, Yefremov N, Mor M, et al. 67Ga scintigraphy and 18F FDG coincidence imaging in the evaluation of lymphoma [abstract]. J Nucl Med 2000;41:141P.
212. Jacobson AF, Maisey MN, Fogelman I. Yield of FDG-PET scans for identifying active malignancy in patients with elevated tumour markers [abstract]. J Nucl Med 1999;40:101P–102P.
213. Jacobson AF, Maisey MN, Fogelman I, Kuhn D. Yield of FDG-PET scanning as a routine follow-up exam in patients with malignancy [abstract]. J Nucl Med 2000;41:304P.
214. Jadvar H, Fischman AJ. Clinical impact of FDG PET on the management of patients with pancreatic carcinoma: comparison with CT and CA19-9 serology [abstract]. J Nucl Med 1999;40:104P.
215. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25:48–51.[Medline]
216. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun 1998;19:547–554.[Medline]
217. Jansson T, Westlin JE, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470–1477.[Abstract]
218. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540–548.[Medline]
219. Jerusalem G, Beguin Y, Fasotte M, et al. Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429–433.[Abstract/Free Full Text]
220. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 2000;85:613–618.[Abstract/Free Full Text]
221. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun 1999;20:13–20.[Medline]
222. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR 1994;163:1459–1465.[Abstract/Free Full Text]
223. Kalff V, Hicks RJ, McManus M, et al. The clinical impact of PET scanning in patients with lung cancer: a prospective [abstract]. J Nucl Med 1998;39:249P.
224. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-(18F)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175–181.[Medline]
225. Kato T, Tsukamoto E, Shiga T, et al. Preliminary results of whole body FDG-PET in biliary carcinoma [abstract]. J Nucl Med 2000;41:298P.
226. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation of F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997;22:332–337.[Medline]
227. Kerrou K, Montravers F, Grahek D, Younsi N, de Beco V, Talbot JN. Follow-up of ovarian cancer using (18F)-FDG scan with a dual-head coincidence gamma camera (CDET) [abstract]. J Nucl Med 2000;41:302P.
228. Keyes JW Jr, Chen MY, Watson NE Jr, Greven KM, McGuirt WF, Williams DW III. FDG PET evaluation of head and neck cancer: value of imaging the thorax. Head Neck 2000;22:105–110.[Medline]
229. Kim DG, Kim CY, Paek SH, et al. Whole-body [18F]FDG PET in the management of metastatic brain tumours. Acta Neurochirurg 1998;140:665–684.
230. Kim JH, Choi CW, Kim BG, et al. FDG-PET in patients with cervical cancer of uterus: experience in patients with clinically no evidence of disease [abstract]. J Nucl Med 2000;41:300P.
231. Kim S, Park CH, Han MH, et al. How useful is 18F-FDG coincidence detection positron emission tomography in the staging of lung cancer? J Nucl Med 2000;41:296P–297P.
232. Kincaid PK, El-Saden SM, Park SH, Goy BW. Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT [see comments]. Am J Neuroradiol 1998;19:801–806.[Abstract]
233. Kluge R, Berr F, Schmidt F, et al. Value of 18F-FDG PET in detection and staging of perihilar cholangiocarcinoma [abstract]. J Nucl Med 2000;41:36P.
234. Klutmann S, Bohuslavizki KH, Buchert R, et al. Impact of 18F-FDG-PET in patients with cancer of unknown primary [abstract]. J Nucl Med 1999;40:259P.
235. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982–988.[Abstract/Free Full Text]
236. Knuuti M, Saraste M, Nuutila P. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994;127:785–796.[Medline]
237. Kole A, Plukker J, Nieweg O, Vaalburg W. Positron emission tomography for staging of gastroesophageal malignancy. Br J Cancer 1998;78:521–527.[Medline]
238. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160–1166.[Medline]
239. Kole AC, Nieweg OE, Pruim J, et al. Whole-body PET with FDG: detection of unknown primary tumors [abstract]. J Nucl Med 1995;36:57P.
240. Kole AC, Nieweg OE, van Ginkel RJ, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol 1997;4:57–63.[Medline]
241. Kostakoglu L, Leonard JP, Coleman M, Kuji I, Vallabhajosula S, Goldsmith SJ. Evaluation of FDG-PET in the detection of bone marrow involvement in lymphoma [abstract]. J Nucl Med 2000;41:71P.
242. Kostakoglu L, Leonard JP, Coleman M, Kuji I, Vallabhajosula S, Goldsmith SJ. Comparison of FDG-PET and 67Ga SPECT in the staging of lymphoma [abstract]. J Nucl Med 2000;41:118P.
243. Kosuda S, Grossman HB, Kison PV, Wahl RL. Preliminary FDG-PET study in patients with bladder cancer [abstract]. J Nucl Med 1996;37:260P.
244. Kraemer DLA, Griebel ML, Lee N, Friedman AH, Radtke RA. Surgical outcome in patients with epilepsy with occult vascular malformations treated with lesionectomy. Epilepsia 1998;39:600–607.[Medline]
245. Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761–767.[Medline]
246. Kuehnel G, Rades D, Wildfang I, et al. Whole-body positron emission tomography (PET) with 18F-FDG in patients with cancer of unknown primary [abstract]. J Nucl Med 2000;41:300P.
247. Kunkel M, Kuffner HD, Reichert TE, Benz P, Förster GJ, Wagner W. (18F)-2-fluorodeoxyglucose PET. Prospects for secondary prevention of mouth cavity carcinoma [in German]. Mund Kiefer Gesichtschirurg 2000;4:105–110.
248. Kurtaran A, Becherer A, Poetzi C, et al. Limited value of (18F)FDG-PET in localizing of recurrent/metastatic medullary thyroid carcinoma (MTC) [abstract]. J Nucl Med 2000;41:308P.
249. Kutlu CA, Pastorino U, Maisey M, Goldstraw P. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer 1998;21:177–184.[Medline]
250. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703–707.[Abstract/Free Full Text]
251. Lang O, Bihl H. Carcinoma of unknown primary (CUP): value of whole-body F-18-FDG-PET for detection of the primary tumor [abstract]. J Nucl Med 1999;40:259P.
252. Lang O, Brouwers AH, Mergenthaler HG, Doerr U, Bihl H. Value of whole-body 18F-FDG-PET in metastatic renal cell carcinoma: correlation with tumor aggressiveness [abstract]? J Nucl Med 2000;41:117P.
253. Lang O, Doerr U, Merkle P, Bihl H. Whole-body 18F-FDG-PET in patients with suspected recurrence of colorectal cancer: a comparison with CT and MRI [abstract]. J Nucl Med 2000;41:35P.
254. Lang O, Doerr U, Schneider K, Hagen R, Bihl H. Cervical lymph node staging in patients with head and neck cancer: a comparison between 18F-FDG-PET and ultrasound [abstract]. J Nucl Med 2000;41:32P.
255. Laningham FH, Smith GT, Hanna WT, Hubner KF. The impact of whole body FDG PET on the management of patients with malignant melanoma [abstract]. Clin Positron Imaging 1998;1:262.[Medline]
256. Lapela M, Eigtved A, Jyrkkiö S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858–867.
257. Lapela M, Grénman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995;197:205–211.[Abstract/Free Full Text]
258. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35:1076–1082.
259. Leiderman DB, Balish M, Sato S, et al. Comparison of PET measurements of cerebral blood flow and glucose metabolism for the localization of human epileptic foci. Epilepsy Res 1992;13:153–157.[Medline]
260. Lenzo NP, Shulkin B, Castle VP, Hutchinson RJ. FDG PET in childhood soft tissue sarcoma [abstract]. J Nucl Med 2000;41:96P.
261. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265–1266.[Medline]
262. Li PY, Mozley PD, Zhuang HM, et al. Effectiveness of FDG PET in the detection of recurrent squamous cell carcinoma of the head and neck [abstract]. J Nucl Med 2000;41:32P.
263. Lin PC, Chu J, Pocock N. 18F fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid FDG-PET) for staging of lymphoma: comparison with 67Ga scintigraphy [abstract]. J Nucl Med 2000;41:118P.
264. Lin PC, Chu J, Pocock N, Quach T, Sorensen B. F-18 FDG imaging with coincidence dual-head gamma camera (co-PET) in staging of lymphoma: comparison with CT and gallium scans [abstract]. J Nucl Med 1999;40:62P.
265. Lindholm P, Leskinen-Kallio S, Minn H, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 1993;34:1711–1716.[Abstract/Free Full Text]
266. Liu RS, Chu LS, Lee CH, et al. Limited usefulness of (11C)acetate whole body PET in patients with thyroid cancer [abstract]. J Nucl Med 2000;41:310P.
267. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ. A six-hour study of soft tissue masses using FDG PET [abstract]. J Nucl Med 1998;39:255P.
268. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22–30.[Medline]
269. Lonneux M, Borbath I, Bausart R, Pauwels S. The role of PET-18FDG in detecting distant recurrence of breast cancer [abstract]. J Nucl Med 1999;40:250P.
270. Lonneux M, Delval D, Bausart R, et al. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. Nucl Med Commun 1998;19:1047–1054.[Medline]
271. Lowe V, Boyd J, Dunphy F, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651–658.[Abstract/Free Full Text]
272. Lowe V, Dunphy F, Varvares M, et al. Evaluation of chemotherapeutic response in patients with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666–674.[Medline]
273. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075–1084.[Abstract]
274. Lowe VJ, Kim H, Boyd JH, Eisenbeis JF, Dunphy FR, Fletcher JW. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. Radiology 1999;212:799–802.[Abstract/Free Full Text]
275. Lowe VJ, Naunheim KS, Dunphy FR, Kim HJ, Fletcher JW. Evaluation of diagnostic testing discrepancies in the management of lung cancer: a review incorporating (F-18)FDG-PET imaging [abstract]. J Nucl Med 1998;39:248P.
276. Lucas JD, O’Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999;86:550–556.[Medline]
277. Lucas JD, O’Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg. [British volume] 1998;80:441–447.
278. Lucignani G, Paolini G, Landoni C. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxybutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874–881.[Medline]
279. Lucignani G, Tassi L, Fazio F, et al. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related? Eur J Nucl Med 1996;23:1498–1507.[Medline]
280. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133–1137.[Abstract/Free Full Text]
281. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997;64:765–769.[Abstract/Free Full Text]
282. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770–1776.[Abstract]
283. Maes A, Borgers M, Flameng W. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT: correlation with histologic and positron emission tomographic studies and functional follow up. J Am Coll Cardiol 1997;29:62–68.[Abstract]
284. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg 1999;40:741–748.[Medline]
285. Maisey M, Wahl R, Barrington S. Atlas of Clinical Positron Emission Tomography London, UK: Arnold, Hodder Headline Group; 1999.
286. Maisey NR, Hill ME, Webb A, et al. Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000;36:200–206.
287. Maldonado A, Sancho F, Calvo F, et al. The role of FDG-PET in diagnosing suspected tumor recurrence based on increased levels of plasma markers [abstract]. Clin Positron Imaging 1998;1:246.[Medline]
288. Manolidis S, Donald PJ, Volk P, Pounds TR. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolaryngol 1998;534.(suppl):1–11.
289. Markand ON, Salanova V, Worth R, Park HM, Wellman HN. Comparative study of interictal PET and ictal SPECT in complex partial seizures. Acta Neurol Scand. 1997;95:129–136.[Medline]
290. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803–809.[Abstract/Free Full Text]
291. Martin L, Fazel A, Burton F, Fletcher JW. Performance of dedicated, non-attenuation corrected FDG-PET in diagnosis and staging of pancreatic cancer (PCa) [abstract]. J Nucl Med 2000;41:35P–36P.
292. Martinez-Lazaro R, Cortes-Blanco A, Zhuang HM, Alavi AA. Diagnostic performance of whole-body FDG-PET and CT imaging in malignant lymphomas [abstract]. J Nucl Med 2000;41:277P.
293. Matthies A, Smith RJ, Cuchiara AJ, Alavi AA. Dual time point 18FDG-PET imaging for the differentiation between benign and malignant pulmonary nodules [abstract]. J Nucl Med 2000;41:293P.
294. Melchior SW, Fichtner J, Jones J, et al. Changes in fluorodeoxyglucose (FDG) uptake measured by positron emission tomography (PET) in prostate cancer (CaP) patients following androgen withdrawal [abstract]. J Urol 1999;161:297.
295. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer. Comparison with computed tomography. Clin Nucl Med. 2000;25:882–887.[Medline]
296. Menda Y, Bushnell DL, Madsen MT, Kernstine KH, McLaughlin K, Hichwa RD. Retrospective analysis of standardized uptake values of lung masses with 18F FDG PET [abstract]. J Nucl Med 2000;41:295P.
297. Meta J, Valk P, Ariannejad M, et al. Impact of FDG-PET on management of patients with colorectal cancer [abstract]. J Nucl Med 2000;41:299P.
298. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia. J Neural Transm 1998;53:237–250.
299. Mielke R, Pietrzyk U, Jacobs A, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern [see comments]. Eur J Nucl Med 1994;21:1052–1060.[Medline]
300. Mielke R, Schroeder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer’s disease. Acta Neuropathol 1996;91:174–179.[Medline]
301. Mikhaeel NG, Timothy AR, Hain SF, O’Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11.(suppl 1):147–150.
302. Montravers F, Grahek D, Kerrou K, de Beco V, Younsi N, Talbot JN. Comparison of FDG scan on a dual-head coincidence gamma camera (CDET) and conventional imaging for the diagnosis of recurrence of colorectal cancer [abstract]. J Nucl Med 2000;41:300P.
303. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795–800.[Abstract/Free Full Text]
304. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475–481.[Abstract/Free Full Text]
305. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407–1413.[Abstract/Free Full Text]
306. Moon D, Maddahi J, Silverman D, Glaspy J, Phelps M, Hoh C. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431–435.[Abstract/Free Full Text]
307. Mruck S, Baum RP, Rinne D, Hoer G. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics. Anticancer Res 1999;19:2685–2690.[Medline]
308. Mueller SP, Goerges R, Brandt-Mainz K, Bockisch A. The role of FDG-PET and 201Tl imaging as a preoperative diagnostic tool in recurrent Hürthle cell carcinoma of the thyroid [abstract]. J Nucl Med 2000;41:306P.
309. Mukahira K, Oguni H, Awaya Y, et al. Study on surgical treatment of intractable childhood epilepsy. Brain Dev 1998;20:154–164.[Medline]
310. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery (St. Louis) 1997;122:1049–1061.[Medline]
311. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 1998;27:342–347.[Medline]
312. Nakamoto Y, Higashi T, Sakahara H, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999;54:248–252.[Medline]
313. Nakamoto Y, Saga T, Ishimori T, et al. Clinical contribution of FDG-PET for follow-up patients with gynecological malignancies [abstract]. J Nucl Med 2000;41:301P.
314. Nettelbladt OS, Sundin AE, Valind SO, et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998;39:640–647.[Abstract/Free Full Text]
315. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111–116.[Abstract/Free Full Text]
316. Nguyen A, Akhurst T, Larson S, Coit D, Brady M. PET Scanning with 18F2-fluoro-2-deoxy-D-glucose(FDG) in patients with melanoma: benefits and limitations. Clin Positron Imaging 1999;2:93–98.[Medline]
317. Nieweg O, Kim E, Wong W, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920–3925.[Medline]
318. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257–261.[Abstract/Free Full Text]
319. Nitzsche EU, Hoh CK, Dalbohm NM, et al. Whole body positron emission tomography in breast cancer [in German]. Rofo Fortschr Geb Rontgenstr 1993;158:293–298.
320. Nitzsche EU, Simon GH, Krautmann F, et al. Is FDG PET indicated when cancer disease of the pancreas is diagnosed based on CT [abstract]? J Nucl Med 1997;38:144P.
321. Noh D, Yun I, Kim J, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg. 1998;22:223–228.[Medline]
322. Noh DY, Yun IJ, Kang HS, et al. Detection of cancer in augmented breasts by positron emission tomography. Euro J Surg. 1999;165:847–851.
323. Nowak B, Di Martino E, Jänicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999;38:312–318.[Medline]
324. Nunez RF, Yeung HW, Macapinlac HA, Larson SM. Does post radiation therapy change in the lung affect the accuracy of FDG-PET in the evaluation of tumor recurrence in lung cancer [abstract]? J Nucl Med 1999;40:234P.
325. Nuutinen J, Leskinen S, Elomaa I, et al. FDG-PET imaging of residual testicular cancer after chemotherapy [abstract]. J Nucl Med 1996;37:256P.
326. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613–620.[Medline]
327. Orino K, Kawamura M, Hatazawa J, Suzuki I, Sazawa Y. Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules [in Japanese]. Jpn J Thorac Cardiovasc Surg 1998;46:1267–1274.[Medline]
328. Oriuchi N, Ichikawa A, Koyama K, et al. Clinical significance of L-(3-18F)- alpha-methyl tyrosine PET studies in intracranial and intrathoracic tumor: a comparative study with 18F-FDG PET [abstract]. J Nucl Med 2000;41:291P–292P.
329. Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999;29:623–629.[Abstract/Free Full Text]
330. Oyama N, Akino H, Suzuki Y, et al. FDG-PET for evaluating the effectiveness of endocrine therapy for prostate cancer [abstract]. J Nucl Med 1999;40:256P–257P.
331. Oyen WJ, Neeleman N, Ruers TJ, Jager GJ, Wobbes T, Corstens FH. FDG-PET in metastasized colorectal carcinoma [abstract]. J Nucl Med. 2000;41:35P.
332. Pai M, Park CH, Suh JH, Koh JH. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Clin Nucl Med 1999;24:495–500.[Medline]
333. Palmedo H, Bender H, Grünwald F, Mallmann P, Krebs D, Biersack H. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med 1997;24:1138–1145.[Medline]
334. Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology 2000;200:167–169.[Medline]
335. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617–1621.[Abstract/Free Full Text]
336. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487–490.[Abstract/Free Full Text]
337. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F-18)-12-deoxy-D-glucose. Radiology 1994;191:379–382.[Abstract/Free Full Text]
338. Paulus P, Sambon A, Vivegnis D, et al. 18FDG PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998;108:1578–1583.[Medline]
339. Pawlik G, Holthoff VA, Kessler J, et al. Positron emission tomography findings relevant to neurosurgery for epilepsy. Acta Neurochirurg 1990;50. (suppl):84–87.
340. Peterson LM, Graham MM, Hayward RM, Yeung RS, Hansen PD. FDG PET identify residual or recurrent disease following local ablation of liver metastases [abstract]. J Nucl Med 2000;41:287P.
341. Präuer HW, Weber WA, Römer W, Treumann T, Ziegler SI, Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998;85:1506–1511.[Medline]
342. Que TH, Plukker JT, Vaalburg W. Staging of gastroesophageal cancer with PET using 11C choline and 18F FDG [abstract]. J Nucl Med 2000;41:141P.
343. Raja S, Fernandez-Vicioso E, Suh JH, et al. Brain tumor recurrence versus radiation necrosis: role of Tc-99m MIBI compared to FDG PET [abstract]. J Nucl Med 1997;38:153P.
344. Rakotonirina H, Delahaye N, Crestani B, et al. Preoperative staging of patients (PTS) with non-small cell lung cancer (NSCLC) using 18FDG imaging: comparison of dual-head coincidence (DHC) gamma-camera versus dedicated PET [abstract]. J Nucl Med 2000;41:292P.
345. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998;53:659–665.[Medline]
346. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047–3058.[Medline]
347. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993;72:82–90.[Medline]
348. Richter J, Garcia-Velloso M, Perez-Equiza C, et al. PET-FDG versus CT in the staging and detection of relapse in patients with Hodgkin’s disease or non-Hodgkin lymphoma: two years experience [abstract]. Clin Positron Imaging 1998;1:248.[Medline]
349. Rinne D, Baum RP, Hör G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664–1671.[Medline]
350. Rintahaka PJ, Chugani HT. Clinical role of positron emission tomography in children with tuberous sclerosis complex. J Child Neurol 1997;12:42–52.[Abstract/Free Full Text]
351. Römer W, Avril N, Dose J, et al. Metabolic characterization of ovarian tumors with positron emission tomography and F-18 fluorodeoxyglucose. Rofo Fortschr Geb Rontgenstr. 1997;166:62–68.
352. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41–45.[Abstract/Free Full Text]
353. Rostom AY, Powe J, Kandil A, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999;72:1064–1068.[Abstract]
354. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ. Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neuro-Oncol 1993;15:57–66.[Medline]
355. Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195–1204.[Medline]
356. Ryu JS, Choi NC, Fischman AJ. FDG-PET in evaluating therapeutic effect and restaging of non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology [abstract]. J Nucl Med 1999;40:246P.
357. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers [see comments]. Cancer J Sci Am 1999;5:214–218.[Medline]
358. Salanova V, Markand O, Worth R, et al. Presurgical evaluation and surgical outcome of temporal lobe epilepsy. Pediatr Neurol 1999;20:179–184.[Medline]
359. Salanova V, Markand O, Worth R, et al. FDG-PET and MRI in temporal lobe epilepsy: relationship to febrile seizures, hippocampal sclerosis and outcome. Acta Neurol Scand 1998;97:146–153.[Medline]
360. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer’s disease with PET. J Nucl Med 1994;35:391–398.[Abstract/Free Full Text]
361. Sanz G, Robles JE, Giménez M, et al. Positron emission tomography with 18-fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. Br J Urol Int 1999;84:1028–1031.
362. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741–747.[Medline]
363. Saunders CAB, Dussek JE, O’Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790–797.[Abstract/Free Full Text]
364. Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry 1993;56:615–621.[Abstract/Free Full Text]
365. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417–421.[Abstract]
366. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative [18F] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618–623.[Medline]
367. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–1695.[Abstract/Free Full Text]
368. Schiepers C, Meta J, Yap CS, et al. Characterization of solitary pulmonary nodules and lung cancer with FDG-PET [abstract]. J Nucl Med 2000;41:296P.
369. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517–522.[Medline]
370. Schiepers C, Yap CS, Meta J, et al. Staging of recurrent lung cancer: value of FDG-PET in therapy selection and management of patients [abstract]. J Nucl Med 2000;41:75P.
371. Schiepers C, Yap CS, Silverman DH, et al. Staging of newly diagnosed lung cancer: impact of FDG-PET on patient management [abstract]. J Nucl Med 2000;41:109P.
372. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381–2389.[Abstract/Free Full Text]
373. Schirrmeister H, Guhlmann CA, Diederichs CD, Trager H, Reske SN. Planar bone imaging vs 18F-PET in patients with cancer of the prostate, thyroid and lung [abstract]. J Nucl Med 1998;39:113P–114P.
374. Schirrmeister HH, Kuehn T, Buck AK, Reske SN. FDG-PET in preoperative staging of breast cancer [abstract]. J Nucl Med 2000;41:28P.
375. Schirrmeister HH, Staib L, Buck AK, Guhlmann CA, Reske SS. FDG-PET in patients with suspected recurrence of colorectal cancer. Is there a contribution to surgical decision finding [abstract]? J Nucl Med 2000;41:297P.
376. Schlüter B, Grimm-Riepe C, Beyer W, Lübeck M, Schirren-Bumann K, Clausen M. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer. Langenbecks Arch Surg 1998;383:187–189.[Medline]
377. Schöder H, Campisi R, Ohtake T, et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol 1999;33:1328.– 1337.[Abstract/Free Full Text]
378. Schoenberger JA, Bergner U, Maag K, Eilles C. Comparison of hybrid PET system and dedicated PET-scanner in patients with colon cancer and indeterminate liver lesion [abstract]. J Nucl Med 2000;41:291P.
379. Schulte M, Brecht-Krauss D, Heymer B, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999;26:599–605.[Medline]
380. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 1999;19:1343–1350.[Medline]
381. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380–386.[Medline]
382. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642–648.[Abstract/Free Full Text]
383. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994;58:698–703.[Abstract]
384. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162:1322–1328.[Medline]
385. Seltzer MA, Strum SB, Scholz MC, et al. Comparison of whole-body 11C acetate and FDG PET in patients with prostate cancer [abstract]. J Nucl Med 2000;41:142P.
386. Seltzer MA, Valk PE, Wong CS, et al. Prospective survey of referring physicians to determine the impact of whole-body FDG-PET on management of cancer patients [abstract]. J Nucl Med 2000;41:108P.
387. Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, Wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 2000;73:482–487.[Abstract]
388. Shankar LK, Yamamoto AJ, Alavi AA, Mandel S. The clinical utility of 18FDG PET in the management of iodine-negative thyroid cancer [abstract]. J Nucl Med 2000;41:310P.
389. Shields AF, Ahmed S, Zalupski MM, et al. FDG-PET evaluation of pancreatic cancer treatment [abstract]. J Nucl Med 1999;40:243P.
390. Shih YH, Yiu CH, Su MS, et al. Temporal lobectomy in adults with intractable epilepsy. J Formosan Med Assoc 1994;93:307–313.[Medline]
391. Shreve P, Grossmann H, Gross M, Wahl R. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 1996;199:751–756.[Abstract/Free Full Text]
392. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998;207:431–437.[Abstract/Free Full Text]
393. Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-(F-18)-fluoro-2-deoxy-D-glucose PET studies. Radiology 1995;194:495–500.[Abstract/Free Full Text]
394. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-(fluorine-18)fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35–41.[Abstract/Free Full Text]
395. Silverman DH, Chang CY, Cummings JL, et al. Prognostic value of regional brain metabolism in evaluation of dementia: comparison with long-term clinical outcome [abstract]. J Nucl Med 1999;40:71P.
396. Silverman DH, Lu CS, Czernin J, Small GW, Phelps ME. Prognostic value of brain PET in patients with early dementia symptoms, treated or untreated with anticholinesterase therapy [abstract]. J Nucl Med 2000;41:64P.
397. Silverman DH, Small GW, Kung de Aburto MA, et al. Diagnostic accuracy of FDG-PET in evaluation of dementia: international multi-center pooled brain scan and autopsy data [abstract]. J Nucl Med 2000;41:63P.
398. Slosman DO, Spiliopoulos A, Couson F, et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun 1993;14:955–961.[Medline]
399. Smith G, Hubner K, McDonald T, Thie J. Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET [abstract]. Clin Positron Imaging 1998;1:263.[Medline]
400. Smith I, Ogston K, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998;228:220–227.[Medline]
401. Smith IC, Welch A, Chilcott F, et al. 18F-FDG PET may predict the pathological response of breast cancer to primary chemotherapy [abstract]. J Nucl Med 1999;40:137P.
402. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–1688.[Abstract/Free Full Text]
403. Snead OC III, Chen LS, Mitchell WG, et al. Usefulness of [18F]fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. Pediatr Neurol 1996;14:98–107.[Medline]
404. Spaepen K, Stroobants S, Dupont P, et al. Positron emission tomography with fluorodeoxyglucose after first line chemotherapy in non-Hodgkin’s lymphoma [abstract]. J Nucl Med 2000;41:70P.
405. Stefan H, Pawlik G, Böcher-Schwarz HG, et al. Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT and PET. J Neurol 1987;234:377–384.[Medline]
406. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441–446.[Abstract/Free Full Text]
407. Steinert HC, Huch Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705–709.[Abstract/Free Full Text]
408. Steinert HC, Voellmy DR, Trachsel C, et al. Planar coincidence scintigraphy and PET in staging malignant melanoma [abstract]. J Nucl Med 1998;39:1892–1897.[Abstract/Free Full Text]
409. Steinert HC, Von Schulthess GK, Weder W. Effectiveness of whole-body FDG PET imaging in staging of non-small-cell lung cancer (NSCLC) [abstract]. J Nucl Med 1998;39:80P.
410. Stokkel M, Stevens H, Taphoorn M, Van Rijk P. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera. A pilot study. Nucl Med Commun 1999;20:411–417.[Medline]
411. Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 1999;26:1606–1609.[Medline]
412. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 1999;26:767–773.[Medline]
413. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation [see comments]. Radiology 1995;195:339–344.[Abstract/Free Full Text]
414. Stumpe K, Urbinelli M, Steinert H, Glanzmann C, Buck A, von Schulthess G. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–728.[Medline]
415. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999;40:1125–1131.[Abstract/Free Full Text]
416. Sugawara Y, Wald JJ, McGillicuddy JE, Carlson SM, Wahl RL. FDG-PET in evaluation of brachial plexopathy in patients with previously-treated breast cancer [abstract]. J Nucl Med 1999;40:137P–138P.
417. Swartz BE, Halgren E, Delgado-Escueta AV, et al. Neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia 1989;30:547–558.[Medline]
418. Szelies B, Grond M, Herholz K, Kessler J, Wullen T, Heiss WD. Quantitative EEG mapping and PET in Alzheimer’s disease. J Neurol Sci 1992;110:46–56.[Medline]
419. Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg 1999;86:932–937.[Medline]
420. Tamaki N, Kawamoto M, Tadamura E. Prediction of reversible ischemia after revascularization: perfusion and metabolic studies with positron emission tomography. Circulation 1995;91:1697–1705.[Abstract/Free Full Text]
421. Tamaki N, Yoshiharu Y, Yamashita K. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860–865.[Medline]
422. Tanaka F, Yonekura Y, Ikeda A, et al. Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: comparison with brain perfusion SPET and FDG PET. Eur J Nucl Med 1997;24:27–34.[Medline]
423. Tatsumi M, Tokita N, Nishimura T. Whole-body hybrid positron emission tomography with 18F-FDG in the staging of non-Hodgkin’s lymphoma [abstract]. J Nucl Med 2000;41:292P.
424. Tatsumi M, Yutani K, Watanabe Y, et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999;40:566–573.[Abstract/Free Full Text]
425. Tedeschi E, Hasselbalch SG, Waldemar G, et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 1995;59:608–615.[Abstract/Free Full Text]
426. Theodore WH, Dorwart R, Holmes M, Porter RJ, DiChiro G. Neuroimaging in refractory partial seizures: comparison of PET, CT, and MRI. Neurology 1986;36:750.– 759.[Abstract/Free Full Text]
427. Theodore WH, Sato S, Kufta CV, Gaillard WD, Kelley K. FDG-positron emission tomography and invasive EEG: seizure focus detection and surgical outcome. Epilepsia 1997;38:81–86.[Medline]
428. Thompson TP, Lunsford LD, Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotactic Funct Neurosurg 1999;73:9–14.
429. Tillisch J, Brunken R, Marshall R. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–888.[Abstract]
430. Tomas MB, Manalili E, Leonidas JC, Karayalcin G, Lipton J, Palestro CJ. 18F-FDG imaging of lymphoma in children using a hybrid PET system: comparison with 67Ga [abstract]. J Nucl Med 2000;41:96P.
431. Torizuka T, Nobezawa S, Nagashima S, et al. Role of whole-body FDG-PET in management of patients with recurrent ovarian cancers [abstract]. J Nucl Med 2000;41:303P.
432. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 2000;41:999–1005.[Abstract/Free Full Text]
433. Trieu TC, Littlefield JL, Lowe VJ, Fletcher JW. The efficacy of FDG-PET in the management of non-small cell lung cancer [abstract]. J Nucl Med 1997;38:80P.
434. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314–3319.[Medline]
435. Turlakow A, Yeung HW, Macapinlac HA, Nunez RF, Sanchez AF, Larson SM. Peritoneal carcinomatosis: the role of FDG-PET [abstract]. J Nucl Med 2000;41:36P.
436. Utech C, Young C, Winter P. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588–1593.[Medline]
437. Valk PE, Abella-Columna E, Hasemann MK, et al. Whole-body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503–513.[Abstract/Free Full Text]
438. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573–1581.[Abstract/Free Full Text]
439. Van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996;37:984–990.[Abstract/Free Full Text]
440. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer. A prospective analysis of 50 cases. Chest 1997;112:1480–1486.[Abstract/Free Full Text]
441. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med 1998;25:1495–1501.[Medline]
442. Vaylet F, Foehrenbach H, De Dreuille O, et al. Fluorodeoxyglucose and bronchopulmonary cancer. Initial French results with positron emission tomography [in French]. Rev Pneumol Clin 1998;54:187–195.[Medline]
443. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26.[Medline]
444. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508–1515.[Abstract/Free Full Text]
445. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ III. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181–189.[Medline]
446. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371–377.[Abstract/Free Full Text]
447. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–2111.[Abstract/Free Full Text]
448. Wang H, Maurea S, Mainolfi C, et al. Tc-99m MIBI imaging in patients with lung cancer: comparison with CT and fluorine-18 FDG PET studies [abstract]. J Nucl Med 1996;37:260P.
449. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291–2302.[Abstract/Free Full Text]
450. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802–808.[Abstract/Free Full Text]
451. Weber W, Voll B, Treumann T, Watzlowik P, Praeuer H, Schwaiger M. Imaging of lung cancer: comparison of C-11-methionine and F-18-FDG PET [abstract]. J Nucl Med 1998;39:80P.
452. Weder W, Schmid RA, Bruchhaus H, Hillinger S, Von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886–893.[Abstract/Free Full Text]
453. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759–770.[Medline]
454. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuk Lymphoma 1999;34:545–551.[Medline]
455. Wong CS, Valk P, Ariannejad M, et al. Impact of FDG-PET on management of patients with melanoma [abstract]. J Nucl Med 2000;41:282P.
456. Wong CYO, Pham AN, Welsh RJ, et al. Supra-CT detection of N3 or M1 lesions of NSC lung cancer by 18F FDG PET [abstract]. J Nucl Med 2000;41:294P.
457. Wong WL, Chevretton E, McGurk M, Croft D. PET-FDG imaging in the clinical evaluation of head and neck cancer. J Royal Soc Med 1995;88:469P–473P.
458. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997;22:209–214.[Medline]
459. Yang WI, Choi CW, Lee YS, et al. Whole body (18F) FDG PET in patients with cervical lymph node metastases of unknown primary site [abstract]. J Nucl Med 1999;40:259P–260P.
460. Yap CS, Valk P, Ariannejad M, et al. FDG-PET influences the clinical management of lymphoma patients [abstract]. J Nucl Med 2000;41:70P.
461. Yap CS, Valk P, Ariannejad M, et al. Evaluation of FDG-PET for the clinical management of breast cancer patients [abstract]. J Nucl Med 2000;41:109P.
462. Yasuda S, Makuuchi Y, Sadahiro S, et al. Colorectal cancer recurrence in the liver: detection by PET. Tokai J Exp Clin Med 1998;23:167–171.[Medline]
463. Yeh SDJ, Imbriaco M, Garza D, et al. Twenty percent of bony metastases of hormone-resistant prostate cancer are detected by PET-FDG whole body scanning [abstract]. J Nucl Med 1995;36:198P.
464. Yeung H, Macapinlac H, Mazumdar M, Bains M, Finn R, Larson S. FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 1999;2:255–260.[Medline]
465. Yutani K, Hojo S, Tatsumi M, Shiba E, Noguchi S, Nishimura T. Correlation of F-18-FDG and Tc-99m-MIBI uptake with proliferative activity in breast cancer [abstract]. J Nucl Med 1999;40:16P–17P.
466. Yutani K, Shiba E, Kusuoka H, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000;24:274–280.[Medline]
467. Yutani K, Tatsumi M, Uehara T, Nishimura T. Effect of patients’ being prone during FDG PET for the diagnosis of breast cancer. AJR. 1999;173:1337–1339.[Free Full Text]
468. Yutani K, Uehara T, Nishimura T. Detectability of FDG-PET and MIBI-SPECT to breast tumor [abstract]. J Nucl Med 1997;38:68P.
469. Zeitouni AG, Yamamoto YL, Black M, Gjedde A. Functional imaging of head and neck tumours using positron emission tomography. J Otolaryngol 1994;23:77–80.[Medline]
470. Zhuang HM, Sinha P, Pourdehnad M, Duarte PS, Alavi AA. The crucial role of FDG-PET in the evaluation of liver metastasis from colorectal cancer [abstract]. J Nucl Med 2000;41:35P.
471. Zimny M, Bares R, Frass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678–682.[Medline]
472. Zimny M, Nowak B, Di Martino E, Jaenicke S, Cremerius U, Buell U. Hybrid PET vs. conventional imaging in the diagnosis of head and neck tumors [abstract]. J Nucl Med 2000;41:292P.
473. Zimny M, Schröder W, Wolters S, Cremerisu U, Rath W, Büll U. 18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results [in German]. Nuklearmedizin 1997;36:228–233.[Medline]
474. Zinzani P, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181–1184.[Abstract/Free Full Text]

This article has been cited by other articles:

				D. Ennishi, Y. Maeda, M. Niiya, K. Shinagawa, and M. Tanimoto Incidental Detection of Acute Lymphoblastic Leukemia on [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 20, 2009; 27(36): e269 - e270. [Full Text] [PDF]

				G. B. Fox, C.-L. Chin, F. Luo, M. Day, and B. F. Cox Translational NeuroImaging of the CNS: Novel Pathways to Drug Development Mol. Interv., December 1, 2009; 9(6): 302 - 313. [Abstract] [Full Text] [PDF]

				M. TULLOCH-REID, M. C. SKARULIS, S. I. SHERMAN, N. J. SARLIS, and L. SANTARPIA Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy Anticancer Res, November 1, 2009; 29(11): 4665 - 4671. [Abstract] [Full Text] [PDF]

				E. C. Ford, J. Herman, E. Yorke, and R. L. Wahl 18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy J. Nucl. Med., October 1, 2009; 50(10): 1655 - 1665. [Abstract] [Full Text] [PDF]

				A. Shammas, R. Lim, and M. Charron Pediatric FDG PET/CT: Physiologic Uptake, Normal Variants, and Benign Conditions RadioGraphics, September 1, 2009; 29(5): 1467 - 1486. [Abstract] [Full Text] [PDF]

				D. Y. Lee and K. C. P. Li Systems Diagnostics: The Systems Approach to Molecular Imaging Am. J. Roentgenol., August 1, 2009; 193(2): 287 - 294. [Abstract] [Full Text] [PDF]

				M. Yamato, Y. Kataoka, H. Mizuma, Y. Wada, and Y. Watanabe PET and Macro- and Microautoradiographic Studies Combined with Immunohistochemistry for Monitoring Rat Intestinal Ulceration and Healing Processes J. Nucl. Med., February 1, 2009; 50(2): 266 - 273. [Abstract] [Full Text] [PDF]

				H. Greenspan Super-Resolution in Medical Imaging The Computer Journal, January 1, 2009; 52(1): 43 - 63. [Abstract] [Full Text] [PDF]

				W. Cai, R. Guzman, A. R. Hsu, H. Wang, K. Chen, G. Sun, A. Gera, R. Choi, T. Bliss, L. He, et al. Positron Emission Tomography Imaging of Poststroke Angiogenesis Stroke, January 1, 2009; 40(1): 270 - 277. [Abstract] [Full Text] [PDF]

				B. E. Hillner, B. A. Siegel, A. F. Shields, D. Liu, I. F. Gareen, E. Hunt, and R. E. Coleman Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry J. Nucl. Med., December 1, 2008; 49(12): 1928 - 1935. [Abstract] [Full Text] [PDF]

				S. R. Bayly, R. C. King, D. J. Honess, P. J. Barnard, H. M. Betts, J. P. Holland, R. Hueting, P. D. Bonnitcha, J. R. Dilworth, F. I. Aigbirhio, et al. In Vitro and In Vivo Evaluations of a Hydrophilic 64Cu-Bis(Thiosemicarbazonato)-Glucose Conjugate for Hypoxia Imaging J. Nucl. Med., November 1, 2008; 49(11): 1862 - 1868. [Abstract] [Full Text] [PDF]

				A. Didelot, P. Ryvlin, A. Lothe, I. Merlet, A. Hammers, and F. Mauguiere PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy Brain, October 1, 2008; 131(10): 2751 - 2764. [Abstract] [Full Text] [PDF]

				R. J. Gillies, I. Robey, and R. A. Gatenby Causes and Consequences of Increased Glucose Metabolism of Cancers J. Nucl. Med., June 1, 2008; 49(Suppl_2): 24S - 42S. [Abstract] [Full Text] [PDF]

				B. E. Hillner, B. A. Siegel, D. Liu, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and R. E. Coleman Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry J. Clin. Oncol., May 1, 2008; 26(13): 2155 - 2161. [Abstract] [Full Text] [PDF]

				Y-x He and Q-y Guo Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms Postgrad. Med. J., May 1, 2008; 84(991): 246 - 251. [Abstract] [Full Text] [PDF]

				G. A. Ulaner, P. M. Colletti, and P. S. Conti B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience Radiology, March 1, 2008; 246(3): 895 - 902. [Abstract] [Full Text] [PDF]

				T. Terasawa, T. Nihashi, T. Hotta, and H. Nagai 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review J. Nucl. Med., January 1, 2008; 49(1): 13 - 21. [Abstract] [Full Text] [PDF]

				J. R. Tseng, K. W. Kang, M. Dandekar, S. Yaghoubi, J. H. Lee, J. G. Christensen, S. Muir, P. W. Vincent, N. R. Michaud, and S. S. Gambhir Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET J. Nucl. Med., January 1, 2008; 49(1): 129 - 134. [Abstract] [Full Text] [PDF]

				D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]

				M. Tatsumi, J. H. Miller, and R. L. Wahl 18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies J. Nucl. Med., December 1, 2007; 48(12): 1923 - 1931. [Abstract] [Full Text] [PDF]

				J. M. Hoffman, S. S. Gambhir, and G. J. Kelloff Regulatory and Reimbursement Challenges for Molecular Imaging Radiology, December 1, 2007; 245(3): 645 - 660. [Abstract] [Full Text] [PDF]

				D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]

				R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott The expanding role of PET technology in the management of patients with colorectal cancer Ann. Onc., November 1, 2007; 18(11): 1774 - 1781. [Abstract] [Full Text] [PDF]

				J. M. Hoffman and S. S. Gambhir Molecular Imaging: The Vision and Opportunity for Radiology in the Future Radiology, July 1, 2007; 244(1): 39 - 47. [Abstract] [Full Text] [PDF]

				A. Tan, D. J. Adelstein, L. A. Rybicki, J. P. Saxton, R. M. Esclamado, B. G. Wood, R. R. Lorenz, M. Strome, and M. A. Carroll Ability of Positron Emission Tomography to Detect Residual Neck Node Disease in Patients With Head and Neck Squamous Cell Carcinoma After Definitive Chemoradiotherapy Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 435 - 440. [Abstract] [Full Text] [PDF]

				M. Dandekar, J. R. Tseng, and S. S. Gambhir Reproducibility of 18F-FDG microPET Studies in Mouse Tumor Xenografts J. Nucl. Med., April 1, 2007; 48(4): 602 - 607. [Abstract] [Full Text] [PDF]

				A. V. Taira, R. J. Herfkens, S. S. Gambhir, and A. Quon Detection of Bone Metastases: Assessment of Integrated FDG PET/CT Imaging Radiology, April 1, 2007; 243(1): 204 - 211. [Abstract] [Full Text] [PDF]

				C. G. Radu, C. J. Shu, S. M. Shelly, M. E. Phelps, and O. N. Witte Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis PNAS, February 6, 2007; 104(6): 1937 - 1942. [Abstract] [Full Text] [PDF]

				J. Czernin, M. Allen-Auerbach, and H. R. Schelbert Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as of September 2006 J. Nucl. Med., January 1, 2007; 48(1_suppl): 78S - 88S. [Abstract] [Full Text] [PDF]

				T. A.D. Smith, R. I. Sharma, A. M. Thompson, and F. E.M. Paulin Tumor 18F-FDG Incorporation Is Enhanced by Attenuation of P53 Function in Breast Cancer Cells In Vitro J. Nucl. Med., September 1, 2006; 47(9): 1525 - 1530. [Abstract] [Full Text] [PDF]

				R. L. Korn, A. M. Yost, C. C. May, E. R. Kovalsky, K. M. Orth, T. A. Layton, and D. Drumm Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. Am. J. Roentgenol., July 1, 2006; 187(1): 81 - 85. [Abstract] [Full Text] [PDF]

				D. Delbeke, R. E. Coleman, M. J. Guiberteau, M. L. Brown, H. D. Royal, B. A. Siegel, D. W. Townsend, L. L. Berland, J. A. Parker, K. Hubner, et al. Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0 J. Nucl. Med., May 1, 2006; 47(5): 885 - 895. [Full Text] [PDF]

				E. Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, S. Dick, S. Chow, R. Advani, R. Warnke, S. Kohler, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol, May 1, 2006; 142(5): 577 - 584. [Abstract] [Full Text] [PDF]

				M. E. Juweid and B. D. Cheson Positron-Emission Tomography and Assessment of Cancer Therapy N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507. [Full Text] [PDF]

				G. K. von Schulthess, H. C. Steinert, and T. F. Hany Integrated PET/CT: Current Applications and Future Directions Radiology, February 1, 2006; 238(2): 405 - 422. [Abstract] [Full Text] [PDF]

				M. A. Lodge, R. D. Badawi, R. Gilbert, P. E. Dibos, and B. R. Line Comparison of 2-Dimensional and 3-Dimensional Acquisition for 18F-FDG PET Oncology Studies Performed on an LSO-Based Scanner J. Nucl. Med., January 1, 2006; 47(1): 23 - 31. [Abstract] [Full Text] [PDF]

				R. Scheid, T. Lincke, R. Voltz, D. Y. von Cramon, and O. Sabri Serial 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography and Magnetic Resonance Imaging of Paraneoplastic Limbic Encephalitis Arch Neurol, November 1, 2004; 61(11): 1785 - 1789. [Abstract] [Full Text] [PDF]

				C. K. Abbey, A. D. Borowsky, E. T. McGoldrick, J. P. Gregg, J. E. Maglione, R. D. Cardiff, and S. R. Cherry In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia PNAS, August 3, 2004; 101(31): 11438 - 11443. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck, S. Falen, M. P. Rivera, J. S. Halle, and M. A. Socinski Seeking a Home for a PET, Part 2: Defining the Appropriate Place for Positron Emission Tomography Imaging in the Staging of Patients With Suspected Lung Cancer Chest, June 1, 2004; 125(6): 2300 - 2308. [Abstract] [Full Text] [PDF]

				B. S. Halpern, M. Dahlbom, A. Quon, C. Schiepers, C. Waldherr, D. H. Silverman, O. Ratib, and J. Czernin Impact of Patient Weight and Emission Scan Duration on PET/CT Image Quality and Lesion Detectability J. Nucl. Med., May 1, 2004; 45(5): 797 - 801. [Abstract] [Full Text] [PDF]

				T. Hara, N. Kosaka, T. Suzuki, K. Kudo, and H. Niino Uptake Rates of 18F-Fluorodeoxyglucose and 11C-Choline in Lung Cancer and Pulmonary Tuberculosis: A Positron Emission Tomography Study Chest, September 1, 2003; 124(3): 893 - 901. [Abstract] [Full Text] [PDF]

				E. V. Dizendorf, B. G. Baumert, G. K. von Schulthess, U. M. Lutolf, and H. C. Steinert Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients for Radiation Therapy J. Nucl. Med., January 1, 2003; 44(1): 24 - 29. [Abstract] [Full Text] [PDF]

				M Schwaiger Functional imaging for assessment of therapy Br. J. Radiol., November 1, 2002; 75(90009): S67 - 73. [Full Text] [PDF]

				E. Even-Sapir, H. Lerman, A. Figer, M. Rabau, G. Livshitz, M. Inbar, and M. Gutman Role of 18F-FDG Dual-Head Gamma-Camera Coincidence Imaging in Recurrent or Metastatic Colorectal Carcinoma J. Nucl. Med., May 1, 2002; 43(5): 603 - 609. [Abstract] [Full Text] [PDF]

This Article Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gambhir, S. S. Articles by Phelps, M. E. Search for Related Content PubMed PubMed Citation Articles by Gambhir, S. S. Articles by Phelps, M. E.